NORTHERN TERRITORY OF AUSTRALIA

POISONS AND DANGEROUS DRUGS ACT

As in force at 1 November 1996

Table of provisions

Part V Supply of poisons by pharmacists, medical practitioners, dentists and veterinary surgeons

Part VI Prescriptions

Part VII Hospitals

Part VIII Medical kits

Part IX Records

Part X Storage of poisons

Part XI Schedule 7 substances and pesticides

Part XII Methylated spirits

Part XIII Offences, penalties, investigations, &c.

Part XIV Miscellaneous

The Schedules

NORTHERN TERRITORY OF AUSTRALIA

As in force at 1 November 1996

POISONS AND DANGEROUS DRUGS ACT

An Act to regulate the sale, supply, storage, possession and use of poisons and dangerous drugs, and for related purposes

Part I Preliminary

1 Short title

This Act may be cited as the *Poisons and Dangerous Drugs Act*.

2 Commencement

This Act shall come into operation on a date to be fixed by the Administrator by notice in the *Gazette*.

3 Repeal

The Acts and Ordinances specified in Schedule I are repealed.

4 Savings

(1) Notwithstanding the repeals effected by section 3, the Acts and Ordinances repealed by that section continue to apply to and in relation to an offence committed against an Act or Ordinance so repealed as if this Act had not commenced.

(2) Notwithstanding the repeals effected by section 3, the *Methylated Spirits Regulations* made under the *Methylated Spirits Act* as in force immediately before the commencement of this Act shall continue to apply to and in relation to methylated spirits manufactured in, or brought or imported into, the Territory as if those Regulations were a notice under section 60 made by the Chief Medical Officer on that commencement, and they may be repealed or amended accordingly.

(3) Where, immediately before the commencement of this Act, there was in force a warrant issued under an Act or Ordinance repealed by section 3, or an application had been made to a Justice for the issue of such a warrant which had not, at that commencement, been fully dealt with:

(a) that warrant shall continue in force according to its tenor, and all actions may be duly taken or continued under or in relation to it, as if it were a warrant issued under this Act; and

(b) the application shall be dealt with, and all actions taken in relation to it shall be as valid and effective, as if it were an application for a similar warrant made under this Act,

as the case may be.

5 Crown to be bound

This Act binds the Crown.

6 Interpretation

(1) In this Act, unless the contrary intention appears:

British Pharmacopoeia has the same meaning as it has in the *Therapeutic Goods Act 1966* of the Commonwealth.

cannabis means:

(a) a plant or part of a plant of the genus *Cannabis*;

(b) an extract, resin or tincture of a plant or part of a plant referred to in paragraph (a); or

(c) a preparation or substance containing:

(i) a plant or part of a plant referred to in paragraph (a); or

(ii) an extract, resin or tincture referred to in paragraph (b).

Chief Medical Officer means the person appointed as the Chief Medical Officer under section 5 of the *Public Health Act*.

coca leaf means the leaf of *Erythroxylum truxil-lense*, or the leaf of other species of the genus *Erythroxylum* from which cocaine may be extracted either directly or by chemical trans-formation.

cocaine means methyl-benzoyl laevo-ecgonine with the formula C17H21NO4.

dentist means a dentist or dental specialist registered under the *Dental Act*.

ecgonine means laevo-ecgonine ([a] D20° = -45°6 in 5% solution of water) with the formula C9H15NO3H2O, and all derivatives of laevo-ecgonine which can be used industrially for its recovery.

hazardous substance means a substance specified in Schedule 5.

hospital means a hospital within the meaning of the *Medical Services Act* or a private hospital or nursing home within the meaning of the *Private Hospitals and Nursing Homes Act*.

inspector means an inspector appointed under section 8, and includes the Chief Medical Officer and a member of the Police Force of the rank of Sergeant, Third Class, or above.

licensed retailer means a retailer licensed under Part IV to supply poisons.

methylated spirit means:

(a) a spirit that has been methylated, within the meaning of the *Spirits Act 1906* of the Commonwealth, or denatured;

(b) methyl alcohol or wood spirit;

(c) a spirit to which a methylated substance has been added; or

(d) a drinkable liquid with which a methylated spirit is mixed.

morphine means the principal alkaloid of opium having the formula C17H19NO3.

nurse has the same meaning as in the *Nursing Act*.

opium means the plant *Papaver somniferum* L. or a product of the spontaneously coagulated juice obtained from the capsule of that plant, however small is the content of morphine in that product.

pesticide means a substance or organism manufactured or supplied for:

(a) killing, destroying, attracting, repelling, stupefying, inhibiting the feeding of, directly or indirectly controlling the activity or preventing the infestation or attacks of, insects, pests, vermin or other troublesome or destructive forms of animal life;

(b) killing, destroying or deleteriously affecting the growth or development of any form of plant life or seeds, fruit, foliage or other part of any form of plant life; or

(c) killing, destroying or preventing the attacks of fungi and other parasitic plants, nematodes, bacteria and viruses that affect or which may affect any form of plant life.

pharmacist means a registered pharmacist within the meaning of the *Pharmacy Act*.

pharmacy means the premises on which a pharmacist principally conducts his business as such.

poison means a substance specified in Schedule1, 2, 3, 4, 6, 7 or 8.

prohibited drug means a substance specified in Schedule II.

register means the register kept and maintained under section 52A(2).

registered pesticide means a pesticide registered in the register.

Registrar means the person appointed under section 52A(1) as the Registrar of Pesticides.

Regulations means the Regulations made under this Act.

supply includes sell and exchange.

therapeutic use means a use in or in connection with:

(a) the prevention, diagnosing, curing or alleviation of a disease, ailment or defect in, or injury to, a person or an animal;

(b) the influencing or modifying of a physiological process in a person or an animal;

(c) the testing of the susceptibility of a person or an animal to a disease or ailment; or

(d) the testing of a substance for its efficacy on a person or an animal.

veterinary surgeon means a registered veterinary surgeon within the meaning of the *Veterinary Surgeons Act*.

(2) Subject to subsection (3), a reference in this Act to a substance specified in Schedule II or Schedules 1 to 8 (inclusive) includes a reference to the salts, active principals, alkaloids, derivatives and

stereoisomers (and the salts of stereoisomers) of that substance, where the existence of such salts, active principals, alkaloids, derivatives and stereoisomers is possible, and all preparations and admixtures containing any proportion of that substance unless specifically exempted or, in the case of a substance specified in a schedule in Part B of the schedules to this Act, where the salt, active principal, alkaloid, derivative or stereoisomer (or salt of the stereoisomer) is included in another such schedule.

(3) A reference in this section to a substance specified in Schedule II or Schedules 1 – 8 (inclusive) does not include a reference to a substance or thing that is also specified in Schedule IV.

(4) Where, in this Act or the Regulations, a reference is made to a poison, substance or thing for which there is a description by that name in the British Pharmacopoeia, the reference is to the poison, substance or thing so described.

7 Delegation

(1) The Chief Medical Officer may, by instrument in writing, delegate to a person any of his powers and functions under this Act, other than this power of delegation.

(2) A power or function delegated under this section, when exercised or performed by the delegate, shall, for the purposes of this Act, be deemed to have been exercised or performed by the Chief Medical Officer.

(3) A delegation under this section does not prevent the exercise of a power or the performance of a function by the Chief Medical Officer.

8 Inspectors

The Chief Medical Officer may appoint a person to be an inspector for the purposes of this Act.

9 Powers of inspectors

An inspector may:

(a) enter, at any reasonable time:

(i) premises registered under this Act;

(ii) the business premises of a person licensed or otherwise authorized under this Act to supply poisons; or

(iii) the premises of a person authorized under this Act to possess and use a Schedule 4, 7 or 8 substance for a purpose, other than therapeutic use on the prescription of a medical practitioner, dentist or veterinary surgeon;

(b) enter, at any time, premises in or on which he believes, on reasonable grounds, a poison or hazardous substance is being produced, prepared, manufactured, used, supplied, administered or kept in contravention of this Act;

(c) inspect stocks of poisons or hazardous substances in or on premises referred to in paragraph (a) or (b);

(d) inspect and take copies of, or extracts from, records required to be kept under this Act;

(e) question the occupier, owner of, or person employed in, premises referred to in paragraph (a), or a person in or on premises referred to in paragraph (b), concerning the receipt into or onto, storage or use in or on or disposal from those premises of poisons or hazardous substances, and related matters;

(f) seize a substance which he believes, on reasonable grounds, to be a poison or hazardous substance, where he has reasonable grounds for believing that the substance has been unlawfully obtained or is being, or is intended to be, used for an unlawful purpose or in contravention of this Act; or

(g) order the withdrawal from supply of a poison or hazardous substance which is not packed or labelled in accordance with the requirements of this Act or the Regulations.

Part II Manufacture of poisons

10 Definition

In this Part, ***poison*** does not include a preparation made up:

(a) by a medical practitioner, dentist or veterinary surgeon for the treatment of an individual patient or animal;

(b) by a pharmacist on the prescription of a medical practitioner, dentist or veterinary surgeon; or

(c) for subsequent use by the person making up the preparation, provided that the preparation is not supplied to any other person.

11 Manufacturer to be registered

Subject to this Act, a person shall not produce or manufacture a poison unless the premises on or in which the poison is produced or manufactured are registered under this Part and the poison is a poison, or a poison of a class of poisons, entered in the register in respect of those premises.

Penalty: $2,000 or imprisonment for 12 months.

12 Registration of manufacturer's premises

(1) The owner or occupier of premises on which poisons are or are intended to be produced or manufactured may apply to the Chief Medical Officer to have those premises registered for the production or manufacture of poisons.

(2) An application under subsection (1) shall include:

(a) the name, address and occupation of the applicant;

(b) the nature of the operations to be carried out on the premises and the poison or class of poisons to be included in those operations;

(c) the name, address and occupation of the person who is to be responsible for the operations to be carried out on the premises;

(d) details of the proposed arrangements to be made for the security against theft or unlawful removal of poisons manufactured, produced, stored or used on the premises;

(e) a plan of the premises showing the nature of the operations to be carried out in each section of the premises and the nature and location of security devices; and

(f) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) The Chief Medical Officer may register premises that are the subject of an application under subsection (1) if he is satisfied that, having regard to the nature of the operations to be carried out and the poisons involved:

(a) the person nominated in the application to be responsible for the operation to be carried out on the premises is a fit and proper person to have control of those operations;

(b) the premises are suitable for the purposes of the production or manufacture of poisons; and

(c) the proposed security arrangements for the premises are adequate to safeguard from theft or unlawful removal poisons produced or manufactured on the premises.

(4) Registration under subsection (3) shall be effected by the Chief Medical Officer causing to be entered in a register kept for that purpose:

(a) the name, address and occupation of the owner or occupier of the premises;

(b) the address of the premises;

(c) the name, address and occupation of the person referred to in subsection (3)(a);

(d) the nature of the operations to be carried out on the premises; and

(e) the poison or class of poisons that may be produced, manufactured or used on the premises.

(5) As soon as practicable after the registration of premises under this section, the Chief Medical Officer shall provide the owner or occupier, as the case may be, of the premises with a certificate of registration bearing the details appearing in the register in relation to the premises.

(6) Registration under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months:

(a) on application for renewal, in the prescribed form, being made to the Chief Medical Officer by the registered owner or occupier of the premises; and

(b) on the payment of the prescribed fee.

13 Transfer of registration

(1) The Chief Medical Officer may, in his discretion, on the application of the registered owner or occupier of premises registered under this Part, transfer the registration of those premises from the name of the person appearing on the register as the owner or occupier to the name of the new owner or occupier of the premises and amend the certificate of registration accordingly.

(2) The Chief Medical Officer may remove the name, address and occupation of a person shown in the register as the person responsible for the operations carried out on premises registered under this Part and may substitute the name, address and occupation of another person:

(a) on application being made in the prescribed form by the registered owner or occupier of the premises; and

(b) if the Chief Medical Officer is satisfied that that other person is a fit and proper person to have control of the operations being or to be carried out on the premises,

and amend the certificate of registration accordingly.

14 Display of certificate of registration

The owner or occupier of premises registered under this Part shall:

(a) subject to section 12(5) and to paragraph (b), display and keep displayed his certificate of registration in or on the premises while they remain so registered; and

(b) forward his certificate of registration to the Chief Medical Officer when so required by the Chief Medical Officer.

Penalty: $200.

15 Cancellation of registration

The Chief Medical Officer may cancel the registration of premises under this Part if:

(a) structural alterations are made to the registered premises; or

(b) there is any change in the operations being carried out on, or in the security arrangements in respect of, the premises,

without his prior written approval.

16 Powers of nominated person

A person responsible for the operations being carried out on premises registered under this Part, or a person acting on his behalf, may:

(a) on the premises, be in possession of a poison referred to in the certificate of registration issued under this Part and carry out such operations in relation to it as are specified in that certificate; and

(b) supply a poison to a person who is authorized under this Act to supply or administer that poison to another person.

Part III Control of wholesalers

17 Wholesaler to be registered

(1) A person shall not store a poison for supply by wholesale unless the premises on which the poison is stored are registered under this Part and the poison is a poison, or a poison of a class of poisons, entered in the register in respect of those premises.

Penalty: $2,000 or imprisonment for 12 months.

(2) For the purposes of subsection (1), premises registered under Part II shall be deemed to be registered under this Part in respect of a poison, or a poison of a class of poisons, in relation to those premises, entered in the register kept under that Part.

18 Application for registration

(1) The owner or occupier of premises on which poisons are or are intended to be stored for supply by wholesale may apply to the Chief Medical Officer to have those premises registered for the storage of poisons.

(2) An application under this section shall include:

(a) the name, address and occupation of the applicant;

(b) the poisons to be stored on the premises;

(c) the name, address and occupation of the person who is to be responsible for the storage of poisons on the premises;

(d) details of the proposed arrangements to be made for the security against theft or unlawful removal of poisons stored on the premises;

(e) a plan of the premises showing the nature and location of security devices; and

(f) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) The Chief Medical Officer may register premises that are the subject of an application under subsection (1) if he is satisfied that, having regard to the poisons proposed to be stored on the premises:

(a) the person nominated in the application to be responsible for the storage of those poisons is a fit and proper person to be so responsible;

(b) the premises are suitable for the storage of poisons; and

(c) the proposed security arrangements for the premises are adequate to safeguard from theft or unlawful removal poisons stored on the premises.

(4) Registration under subsection (1) shall be effected by the Chief Medical Officer causing to be entered in a register kept for that purpose:

(a) the name, address and occupation of the owner or occupier of the premises;

(b) the address of the premises;

(c) the name, address and occupation of the person referred to in subsection (3)(a); and

(d) the poison or class of poisons to be stored on and supplied from the premises.

(5) As soon as practicable after the registration of premises under this section, the Chief Medical Officer shall provide the owner or occupier, as the case may be, of the premises with a certificate of registration bearing the details appearing in the register in relation to the premises.

(6) Registration under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months:

(a) on application for renewal, in the prescribed form, being made to the Chief Medical Officer by the registered owner or occupier of the premises; and

(b) on the payment of the prescribed fee.

19 Transfer of registration

(1) The Chief Medical Officer may, in his discretion, on the application of the registered owner or occupier of premises registered under

this Part and the payment of the prescribed fee, transfer the registration of those premises from the name of the person appearing in the register as the owner or occupier to the name of the new owner or occupier of the premises and amend the certificate of registration accordingly.

(2) The Chief Medical Officer may remove the name, address and occupation of a person shown in the register as the person responsible for the storage of poisons on premises registered under this Part and may substitute the name, address and occupation of another person:

(a) on application being made in the prescribed form by the registered owner or occupier of the premises; and

(b) if the Chief Medical Officer is satisfied that that other person is a fit and proper person to have control of the storage of poisons on the premises,

and amend the certificate of registration accordingly.

20 Display of certificate

The owner or occupier of premises registered under this Part shall:

(a) subject to section 18(5) and to paragraph (b), display and keep displayed his certificate of registration in or on the premises while they remain so registered; and

(b) forward his certificate of registration to the Chief Medical Officer when so required by the Chief Medical Officer.

21 Cancellation of registration

The Chief Medical Officer may cancel the registration of premises under this Part if:

(a) the premises are used for the storage of a poison other than a poison in respect of which the premises were registered; or

(b) there is any change in the security arrangements in respect of the premises,

without his prior written approval.

22 Powers of nominated person

A person responsible for the storage of poisons on premises registered under this Part, or a person acting on his behalf, may:

(a) on the premises, be in possession of a poison specified in the certificate of registration issued under this Part in relation to the premises; and

(b) supply a poison specified in the certificate of registration to a person who is authorized under this Act to supply or administer that poison to another person.

Part IV Control of retailers

23 Retailers to be licensed

(1) A person shall not supply a poison by retail unless he is licensed under this Part to supply that poison by retail or is employed by a person who is so licensed.

Penalty: $1,000 or imprisonment for 12 months.

(2) For the purposes of subsection (1), a pharmacist, medical practitioner, dentist or veterinary surgeon shall be deemed to be licensed under this Part in respect of the poisons he is permitted by or under this Act to supply, prescribe or administer.

24 Application for licence

(1) A person may apply to the Chief Medical Officer for a licence to supply a poison by retail.

(2) An application under subsection (1) shall include:

(a) the name, address and occupation of him;

(b) the nature and location of the premises intended to be used by the applicant for the storage and supply of the poison;

(c) the poison or class of poisons that is intended to be supplied; and

(d) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) Subject to subsection (4), the Chief Medical Officer may grant to an applicant a licence to supply by retail a poison if he is satisfied that:

(a) the applicant is a fit and proper person to be granted such a licence and he is not otherwise licensed under this Part; and

(b) the premises proposed to be used for the storage and supply of the poison are adequate for that purpose and constitute one retail outlet only.

(4) A licence granted under this section does not authorize the person to whom it is granted to supply:

(a) a Schedule 3, 4 or 8 substance; or

(b) a Schedule 2 substance, where the premises in respect of which the licence is granted are located within 40 kilometres, by road, of a pharmacy.

(5) A licence granted under this Part shall specify in the licence document:

(a) the poison or class of poisons that the licensee is authorized to supply; and

(b) the premises that may be used for the storage and supply of that poison or a poison included in that class of poisons.

(6) A licence granted under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months:

(a) on application for renewal, in the prescribed form, being made by the licensee during the 28 days immediately preceding the expiration of his licence; and

(b) upon the payment of the prescribed fee.

25 Display of licence

A person licensed under this Part shall:

(a) subject to paragraph (b), display and keep displayed his licence document in or on the premises specified in the licence; and

(b) forward his licence document to the Chief Medical Officer when so required by the Chief Medical Officer.

26 Terms and conditions of licence

(1) A licence granted under this Part may be subject to such terms and conditions as the Chief Medical Officer thinks fit and specifies in the licence document.

(2) The Chief Medical Officer may cancel a licence granted under this Part if:

(a) the licensee is found guilty of an offence against this Act;

(b) the licensee does not comply with the conditions specified in the licence document; or

(c) the he considers it to be in the public interest so to do.

27 Limitation on right of supply

A person licensed under this Part, or a person employed by him may, on the premises specified in the licence document, be in possession of the poison or a poison of a class of poisons specified in the licence document and supply that poison:

(a) in the case of a Schedule 1 substance – to a person who has attained the age of 18 years who is personally known to him or is known to an adult person, known personally by the licensee or person employed by him, as the case may be, who is accompanying that first-mentioned person;

(b) subject to section 24(4), in the case of a Schedule 2 or 6 substance – to any person; and

(c) in the case of a Schedule 7 substance – to a person to whom, under section 54, he may supply that poison.

Part V Supply of poisons by pharmacists, medical practitioners, dentists and veterinary surgeons

28 Supply by pharmacists

(1) Subject to this section and section 35, a pharmacist, or a person employed by him, may produce, manufacture or supply:

(a) a Schedule 1 substance:

(i) where the substance is included in a proprietary prescription intended for therapeutic use;

(ii) in accordance with a written prescription of a medical practitioner, dentist or veterinary surgeon; or

(iii) to a person who has attained the age of 18 years who is personally known to him or who is accompanied by an adult person, known personally by the pharmacist or person employed by him, as the case may be, who is accompanying that first-mentioned person;

(b) a Schedule 2, 3 or 6 substance to any person subject to the recording, in an approved form, of details required by the Chief Medical Officer to be recorded;

(c) a Schedule 4 or 8 substance:

(i) to, or in accordance with a written prescription of, a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth), dentist or veterinary surgeon;

(ii) to a person authorized in writing by the Chief Medical Officer to possess and use the substance; or

(iii) to the master of a ship who is required or permitted, under the Navigation (Orders) Regulations of the Commonwealth, to possess and use that substance; or

(d) a Schedule 7 substance:

(i) to a person authorized in writing by the Chief Medical Officer to possess and use the substance; or

(ii) to, or in accordance with a written prescription of, a medical practitioner, dentist or veterinary surgeon authorized in writing by the Chief Medical Officer to possess, use or prescribe that substance.

(2) Subject to this Act, a Schedule 3 substance may be supplied only by a pharmacist or a person under the direct supervision of a pharmacist.

(3) A poison supplied in accordance with a written prescription of a medical practitioner, dentist or veterinary surgeon shall be made up for supply by a pharmacist or a person under the direct supervision of a pharmacist.

(4) Subject to subsection (1)(c), a pharmacist, or person employed by him, shall not supply a Schedule 4 or 8 substance to, or in

accordance with a written prescription of, a person who is not a registered medical practitioner within the meaning of the *Medical Act* unless he believes, on reasonable grounds, that the person is, or was at the time of writing the prescription, entitled to practise as a medical practitioner under a law in force in the State or another Territory of the Commonwealth in which the prescription was written and:

(a) in the case of a Schedule 4 substance, the pharmacist or person employed by him, as the case may be, is satisfied that a restriction specified in the Schedule in relation to the substance has not been, or will not be, breached; and

(b) in the case of a Schedule 8 substance, the pharmacist or person employed by him, as the case may be, verifies the details of the prescription by speaking or by telephone to, or face to face with, the medical practitioner who issued the prescription..

(5) Nothing in this section entitles a pharmacist, or a person employed by him, to administer a substance referred to in this section except to the extent that a person to whom he supplies it may lawfully administer that substance to himself or to a person in respect of whom it is supplied.

(6) The Chief Medical Officer may, by instrument in writing, authorize a person to obtain from a pharmacist, possess and use a Schedule 4 or 8 substance for a purpose and in accordance with the conditions, if any, specified in the instrument and the person may obtain, possess and use that substance accordingly.

29 Supply of substances for therapeutic use

(1) Subject to this section and section 31 and any other law in force in the Territory, a medical practitioner, dentist or veterinary surgeon may supply a Schedule 1, 2, 3, 4, 7 or 8 substance for the therapeutic use of a particular person or animal.

(2) Subject to section 31, a dentist may sell or supply a Schedule 8 substance only for or in relation to the treatment of a dental condition.

(3) Subject to sections 31 and 31A, a medical practitioner may sell or supply a Schedule 8 substance only for or in relation to the treatment of a medical condition other than addiction.

(4) Subject to section 31, a medical practitioner or veterinary surgeon may sell or supply a Schedule 7 substance only if he has been authorized in writing by the Chief Medical Officer to possess, sell and supply that substance.

(4A) A registered nurse within the meaning of the Nursing Act registered in a category of nursing approved, by notice in the *Gazette*, by the Chief Medical Officer may possess and supply a Schedule 1, 2, 3, 4 or 8 substance in the course of her duties.

(4B) A person who is registered under the *Health Practitioners Act* in the category of registration of dental therapist may possess and supply a Schedule 4 substance, where the possession or supply is in accordance with a determination made, by notice in the *Gazette*, by the Chief Medical Officer.

(4C) A person who is registered under the *Health Practitioners and Allied Professionals Registration Act* in the category of health practice of Aboriginal health work may possess and supply a Schedule 2, 3 or 4 substance, where the possession or supply is approved, in writing, by the Chief Medical Officer

(4D) Where, under subsection (4A), (4B) or (4C), a person supplies a substance, he shall record, in a form approved by the Chief Medical Officer, details of the supply.

(5) In this section:

medical practitioner includes a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth.

sell includes issue a prescription for.

supply includes administer and having in possession for the purpose of supply or administration.

29A Restriction on prescription of amphetamines

(1) Notwithstanding section 29, a medical practitioner shall not prescribe an amphetamine except for a person suffering from narcolepsy or from hyperkinetic brain damage (including attention deficit disorder).

(2) In subsection (1) ***amphetamine*** includes beta-aminoisopropylbenzene and substances structurally derived from amphetamine or beta-aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or both) except when included in Schedule 2, 3 or 4.

30 Pharmacist not to hold certain substances

The Chief Medical Officer may, by notice in writing to a pharmacist, direct the pharmacist not to hold on premises in which he conducts his business a Schedule 8 substance or a Schedule 8 substance specified in the notice except to the extent that is reasonably necessary to enable him to fulfil a prescription after obtaining the substance from a place nominated by the Chief Medical Officer, and the pharmacist shall, accordingly, comply with and not contravene the direction.

Penalty: $2,000 or imprisonment for one year.

31 Medical practitioner, &c., not to possess, &c., certain substances

The Chief Medical Officer may, in his discretion, by notice in writing to a medical practitioner, dentist or veterinary surgeon, prohibit the medical practitioner, dentist or veterinary surgeon from having in his possession, supplying, administering or prescribing a Schedule 8 substance and that person, accordingly, shall not have in his possession, supply, administer or prescribe that substance.

31A Sale or supply of certain substances for treatment of addiction

(1) Subject to this section, the Chief Medical Officer may, in his discretion, by notice in writing to a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth), authorise the medical practitioner to sell or supply a Schedule 8 substance for the treatment of addiction.

(2) The Chief Medical Officer shall only exercise his powers under this section in accordance with the guidelines, from time to time, approved by the Minister.

(3) Where the Chief Medical Officer exercises his discretion under subsection (1), whether it is to authorise or to refuse to authorise the sale or supply of a Schedule 8 substance for the treatment of addiction, he shall provide a report in writing to the Minister containing such information as the Minister may, from time to time, require relating to the operation of this section.

(4) An authorisation under this section may be subject to such conditions, if any, as the Chief Medical Officer thinks fit.

Part VI Prescriptions

32 Application

Unless the contrary intention appears, this Part applies to all prescriptions issued by a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law of a State or another Territory of the Commonwealth) dentist or veterinary surgeon for the supply of a Schedule 1, 4, 7 or 8 substance.

33 Contents of prescriptions

(1) Every prescription to which this Part applies shall:

(a) include the name, professional qualifications, address and telephone number of the person issuing it;

(b) include the date of its issue;

(c) include the name and address of the person to whom the prescription was issued;

(d) be signed by the person who issued it;

(da) where the Chief Medical Officer has, under sub-section (2), directed medical practitioners to comply with requirements when issuing prescriptions, comply with those requirements;

(e) include a statement of the quantity of the substance to be supplied and, where the substance is to be supplied on more than one occasion, include a statement of the quantity to be supplied on each other occasion, and the period that is to elapse before resupply;

(ea) where the substance to be supplied is a Schedule 8 substance:

(i) bear on its face the words "FOR TREATMENT OF A MEDICAL CONDITION OTHER THAN ADDICTION"; or

(ii) where the supply is in accordance with an authorisation under section 31A, bear on its face the words "AUTHORISED FOR SUPPLY FOR TREATMENT OF ADDICTION";

(f) where it is issued by a dentist – bear on its face the words "FOR DENTAL PURPOSES ONLY";

(g) where it is issued by a veterinary surgeon – bear on its face the words "FOR ANIMAL TREATMENT ONLY"; and

(h) include directions for the taking, application or administration of the substance.

(2) Subject to subsection (1), the Chief Medical Officer may direct medical practitioners to comply with requirements specified in the direction when issuing prescriptions.

34 Period of effect of prescription

(1) Subject to this section, a prescription issued in accordance with this Act shall remain in effect only for the period of 12 months from the date of its issue.

(2) A prescription for the supply of a Schedule 8 substance:

(a) shall remain in effect only for 2 months from the date of its issue; and

(b) subject to subsection (2A), shall not provide for more than 2 months supply of the substance.

(2A) A medical practitioner may issue a prescription for more than 2 months supply of a Schedule 8 substance where he has obtained the approval of the Chief Medical Officer to do so.

(3) A person shall not supply to another person a substance that is required under this Act to be supplied only on prescription unless there is a prescription in effect in respect of that supply.

Penalty: $1,000 or imprisonment for 6 months.

35 Endorsement on prescriptions

(1) A pharmacist who supplies a substance in accordance with a prescription to which this Part applies shall, subject to subsection (2), endorse on the face of the prescription:

(a) the date of supply; and

(b) the word "CANCELLED".

(2) Where a prescription is such that it may be used more than once, the pharmacist who supplies a substance in accordance with the prescription shall endorse on the face of the prescription the date of such supply by him of the substance and, where the supply is the last authorized by the prescription, the word "CANCELLED".

36 Record of prescriptions

(1) Subject to this section, a pharmacist shall, as soon as practicable after it is filled, record in a book kept for that purpose, or in some other form approved by the Chief Medical Officer, such details of each prescription filled by him or his employees as the Chief Medical Officer, in writing, directs.

Penalty: $200.

(2) Records kept under this section, and copies of the prescription form endorsed in accordance with section 35 and recorded under subsection (1), shall be retained by the pharmacist for 2 years after the date of the last entry in the record book or other form.

Penalty: $200.

(3) A pharmacist or other person who supplies a Schedule 8 substance in accordance with this Act shall, within 7 days after that supply, forward to the Chief Medical Officer:

(a) the cancelled prescription or a copy of the authority on which he supplied the substance; or

(b) where a prescription authorizes supply on a later occasion – a copy of the prescription.

Penalty: $200.

37 Supply in an emergency

(1) Subject to this section, a pharmacist may supply a Schedule 1, 4, 7 or 8 substance to a person without a prescription where the pharmacist:

(a) believes on reasonable grounds that the situation requires urgent supply; and

(b) has been requested by telephone by a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth), dentist or veterinary surgeon to supply that substance to that person.

(2) Where a pharmacist supplies a substance in pursuance of subsection (1), he shall, as soon as practicable after that supply, obtain a prescription from the medical practitioner, dentist or veterinary surgeon who requested him to supply that substance or, if no such prescription is provided to him within a reasonable time but not later than 3 days after the date of the supply, report in

writing to the Chief Medical Officer the details of that supply.

38 Possession, &c., of Schedule 8 substance

A person may have in his possession, attempt to obtain and use in accordance with the conditions for its use subject to which it was prescribed, a Schedule 8 substance prescribed for use by him, or an animal under his control, by a medical practitioner, dentist or veterinary surgeon.

Part VII Hospitals

39 Liability for safe storage in hospitals

(1) A pharmacist in charge of a pharmacy at a hospital shall be responsible for the safe storage of all poisons received at the hospital and the supply of those poisons in accordance with this Act.

(2) A pharmacist employed at a hospital shall not supply a poison to a person other than:

(aa) a person authorized for the purposes of section 29 or under section 42, to possess the poison;

(a) a nurse employed at the hospital and in accordance with a written requisition of the nurse in charge of a ward or department of the hospital;

(b) a medical practitioner or dentist employed at the hospital and in accordance with a written requisition of that medical practitioner or dentist; or

(c) subject to this Act, in accordance with a prescription issued in accordance with this Act by a medical practitioner or dentist.

(3) A Schedule 1, 3, 4, 7 or 8 substance supplied to or on the written requisition of a nurse in charge of a ward or department of a hospital shall be held by her for the purpose of administration, and shall not be administered except:

(a) to a person who is a patient in that ward or department; and

(b) on the directions of a medical practitioner.

(4) As soon as practicable after a medical practitioner gives a direction for administering a Schedule 1, 3, 4, 7 or 8 substance to a patient in a ward or department of a hospital, he shall sign an entry in that patient's medical record to the effect that he authorized the

administration of that substance and, in the case of a Schedule 8 substance, that entry shall be made and signed before the substance is administered.

Penalty: $200.

40 Register of Schedule 8 substances in wards

(1) The nurse in charge of a ward or department of a hospital, or of a health centre, shall enter in a register kept for that purpose full details of:

(a) all Schedule 8 substances supplied to or for use in that ward or department or in or by that centre; and

(b) each occasion on which a Schedule 8 substance is administered to a patient in that ward or department or in or of that centre.

Penalty: $200.

(2) Details recorded for the purposes of subsection (1)(b) shall include:

(a) the time and date the substance is administered;

(b) the amount administered;

(c) the name of the patient;

(d) the name of the person authorizing the treatment;

(e) the name and signature of the person administering the substance; and

(f) the name and signature of a person referred to in section 41 who witnessed the administration of the substance.

41 Administration of Schedule 8 substance to be witnessed

A Schedule 8 substance shall not be administered to a patient in a ward or department of a hospital, or of a health centre, unless there is present at the time of the administration of the substance a person, other than the patient, who can read English and who witnesses its administration.

Part VIII Medical kits

42 Authorization of poisons in medical kits

The Chief Medical Officer may, in writing, authorize a person to possess a specified quantity of a specified poison where that poison is included in a medical kit and that person may possess that poison accordingly.

43 Administration from medical kits

(1) A person authorized under section 42 to possess a Schedule 4 or 8 substance shall administer that substance only:

(a) to a person whose medical condition, in the opinion of the person administering it, requires its administration; and

(b) where the advice or personal attendance of a medical practitioner is not reasonably available.

(2) Where a Schedule 4 or 8 substance is administered in circumstances described in subsection (1), the person administering it shall, as soon as practicable after administering it, report in writing to the Chief Medical Officer the details of its administration, including details of the kind referred to in section 40(2)(a) to (e) inclusive.

Penalty: $200.

Part IX Records

44 Manufacturers to keep records

A person responsible under this Act for the operations carried out on premises registered under Part II shall keep a record, in a form approved by the Chief Medical Officer, of:

(a) the date of receipt and the quantity and the name and address of the supplier, of each shipment of a poison received into the premises;

(b) the quantities of poisons manufactured, produced or compounded with other substances on the premises, together with the quantities of preparations containing a poison that are produced on the premises;

(c) the date and quantity of each supply of a poison from the premises, together with the name and address of the person to whom the supply was made; and

(d) such other matters as the Chief Medical Officer requires to be recorded.

Penalty: $200.

45 Wholesalers to keep records

A person responsible for the storage of poisons on premises registered, or deemed to be registered, under Part III shall keep a record, in a form approved by the Chief Medical Officer, of:

(a) the date of receipt and the quantity, and the name and address of the supplier, of each shipment of a poison received into the premises;

(b) the date and quantity of each supply of a poison from the premises, together with the name and address of the person to whom the supply was made; and

(c) such other matters as the Chief Medical Officer requires to be recorded.

Penalty: $200.

46 Retailers to keep records

(1) A licensed retailer shall:

(a) retain all delivery dockets and invoices relating to the receipt by him of a poison;

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of each receipt and supply by him of a Schedule 1 or 7 substance; and

(c) where he supplies a Schedule 1 or 7 substance to fill a written order, retain the written order.

Penalty: $200.

(2) Where the supply of a Schedule 1 or 7 substance is conducted in the presence of a licensed retailer or a person acting on his behalf, the purchaser shall sign the register referred to in subsection (1) next to the entry made in relation to that supply.

Penalty: $200.

47 Pharmacists to keep records

(1) Subject to subsection (2), in addition to the records required to be kept by him under Parts VI and VII, a pharmacist shall –

(a) retain all delivery dockets or invoices relating to the receipt by him of a Schedule 1, 7 or 8 substance; and

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of each supply by him of Schedule 1, 4, 7 or 8 substances.

Penalty: $200.

(2) The receipt or supply of a substance referred to in subsection (1)(b) recorded in a prescription book or other form of record approved by the Chief Medical Officer is sufficient compliance with that subsection.

48 Medical practitioner, &c., to keep records

A medical practitioner, dentist or veterinary surgeon shall:

(a) retain all delivery dockets or invoices relating to the receipt by him of a poison; and

(b) enter in a register kept for that purpose or in a form approved by the Chief Medical Officer, details of the supply or administration by him of a Schedule 4, 7 or 8 substance, including the reason for the supply or administration.

Penalty: $200.

49 Authorized persons to keep records

A person authorized by or under this Act to possess and use a Schedule 4, 7 or 8 substance, other than a person obtaining that substance on the prescription of a medical practitioner, dentist or veterinary surgeon, shall:

(a) retain all delivery dockets or invoices relating to the receipt by him of that substance;

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of the supply or administration by him of that substance; and

(c) where that substance is supplied or administered by him to fill a written prescription, retain the prescription.

Penalty: $200.

50 Retention of records

A record, invoice, delivery docket, written order or prescription required by this Part to be kept or retained shall be retained for 2 years after the date of the last entry in the record in which it is recorded.

Penalty: $200.

Part X Storage of poisons

51 Storage to prevent public access

The person in charge of premises in which a Schedule 1, 3, 4 or 7 substance is stored shall:

(a) ensure that the substance is stored in an area and in such a manner as to prevent unauthorized access to it; and

(b) take such measures as are reasonably necessary to prevent unauthorized access to that substance, whether or not the premises are open for business.

Penalty: $200.

52 Storage of Schedule 8 substances

(1) Subject to this section, a person who has in his possession a Schedule 8 substance, other than that supplied on the prescription of a medical practitioner, dentist or veterinary surgeon, shall, except when it is in actual use, keep that substance in a locked room, safe, cupboard or container of a type approved by the Chief Medical Officer.

Penalty: $200.

(2) A pharmacist who has in his possession a Schedule 8 substance shall store that substance in a safe which complies with the specifications the Chief Medical Officer, from time to time, determines.

Penalty: $200

(3) Where a Schedule 8 substance is kept for emergency purposes in the possession of a medical practitioner, dentist or veterinary surgeon, it is sufficient compliance with subsection (1) if that substance is kept:

(a) in a locked bag in the possession of that person; or

(b) in a locked room or motor vehicle, the key of which is in the personal possession of that person.

Part XI Schedule 7 substances and pesticides

52A Registrar of Pesticides and register

(1) The Chief Medical Officer shall appoint an employee as defined in the *Public Sector Employment and Management Act*, who is employed in the Department of Industries and Development to be the Registrar of Pesticides.

(2) The Registrar shall keep and maintain a register of pesticides in which he may register -

(a) pesticides which are registered in a State or another Territory of the Commonwealth; and

(b) other pesticides which, in his opinion, are suitable for use in the Territory as pesticides.

(3) Where, under subsection (2), the Registrar registers a pesticide, he may:

(a) impose, by notation in the Register, conditions in relation to the use of the pesticide so registered; or

(b) specify other purposes for which the pesticide may be used.

53 Possession, &c., of Schedule 7 substances

(1) A person may apply to, and in a form approved by, the Chief Medical Officer or his delegate for authorization to possess and use a Schedule 7 substance.

(2) Subject to section 59, the Chief Medical Officer may authorize a person to possess and use a Schedule 7 substance which is intended for use for an agricultural, horticultural, pastoral or other purpose approved by the Chief Medical Officer, if he is satisfied that that person has sufficient reason to possess and use that substance.

54 Supply of pesticides, &c.

(1) Subject to Parts II to VII inclusive, a person shall not supply to another person a Schedule 7 substance unless he is satisfied by sighting the authorization or licence, or by statutory declaration, of the other person, that:

(a) the other person is entitled under section 58 to possess and use the substance;

(b) the other person is authorized under section 53 to possess and use the substance; or

(c) in his opinion, the other person has a genuine agricultural, horticultural or pastoral use for that substance and has a reasonable under-standing of how safely to use it.

Penalty: $1,000 or imprisonment for one year.

(2) A statutory declaration referred to in sub-section (1) shall be kept by the supplier with the records to which it relates required under Part IX to be kept by him and shall be retained for the period during which those records are required to be retained.

Penalty: $200.

55 Application for licence

(1) A person who uses or applies a registered pesticide for a fee or reward shall, and other persons may, apply to the Chief Medical Officer for a licence to be a pest control operator.

(2) An application under subsection (1) shall include:

(a) the full name and address of the applicant;

(b) the name and address of the applicant's employer, if any;

(c) full details of any Schedule 7 substance proposed to be used by the applicant and the purposes for which it is proposed to be used; and

(d) details of the applicant's experience and training in pest control procedures and the handling of poisons.

56 Grant of licence

(1) Subject to this section, the Chief Medical Officer may grant to an applicant under section 55 a licence to be a pest control operator if he is satisfied, whether by examination or by such other means as he thinks fit, that the applicant has adequate knowledge of:

(a) the properties of the substances proposed to be used;

(b) the proper procedures for the safe storage, handling, application and disposal of the substances proposed to be used;

(c) the symptoms of poisoning by the substances proposed to be used and the correct first aid procedures to be applied in the case of such poisoning; and

(d) the provisions of this Act and the Regulations relating to substances used as or in pesticides.

(2) A licence under this section shall not be granted until the applicant has paid the prescribed fee.

57 Renewal of licence

A licence granted under section 56 shall remain in force for 12 months from the date on which it was granted and may be renewed from time to time for further periods of 12 months on application to the Chief Medical Officer, in a form approved by him, and on payment of the prescribed fee.

58 Authority to possess poisonous substances

A person licensed under section 55, or a person acting under the direct supervision of that person, may possess and use the Schedule 7 substances in respect of which the licence was granted.

59 Medical examination

(1) The Chief Medical Officer may require:

(a) an applicant under section 55;

(b) the holder of a licence granted or renewed under this Part; or

(c) a person who is employed by a person referred to in paragraph (b),

to undergo a medical examination and may, if the results of that medical examination indicate to the satisfaction of the Chief Medical Officer that the use or continued use of the substance used or proposed to be used constitutes a threat to the health of that person:

(d) refuse to grant or renew a licence granted under this Part;

(e) suspend for a specified period a licence granted under this Part, or

(f) order in writing the employer of a person referred to in paragraph (c) to cease to employ that person in any capacity involving the handling of or exposure to such pesticides as are specified in the order.

(2) A person to whom an order under subsection (1) is directed shall comply with and not contravene the order.

Penalty: $200.

59A Offence to deal with unregistered pesticides

(1) A person shall not possess or sell a pesticide other than a registered pesticide.

(2) A person shall not use a registered pesticide except:

(a) where conditions have been imposed under section 52A(3)(a) in relation to the use of the pesticide, in accordance with those conditions;

(b) for a purpose specified under section 52A(3)(b);

(c) for a purpose and in accordance with a schedule in which it is listed; or

(d) for a therapeutic purpose.

Penalty: $500.

Part XII Methylated spirits

60 Additives to methylated spirits

The Chief Medical Officer may, by notice in the *Gazette*, require that methylated spirits manufactured in or brought into the Territory after a date specified in the notice, which is not designated by label to be for industrial purposes or for use by medical practitioners,

dentists, veterinary surgeons or pharmacists in com-pounding medical preparations for external use, shall contain such additional substances, in such proportions, as is specified in the notice.

61 Drinking of methylated spirits

A person who drinks methylated spirits is guilty of an offence.

Penalty: Imprisonment for 3 months.

62 Supply of methylated spirits for drinking

A person who, having reasonable cause to believe that it is intended to be used for drinking purposes by the person to whom it is supplied or by another person, supplies methylated spirits to a person, is guilty of an offence.

Penalty: Imprisonment for 3 months.

63 Possession, &c., of methylated spirits required to be adulterated

(1) A person who supplies or has in his possession or under his control methylated spirits required under section 60 to contain an additional substance which does not contain that additional substance or contains that additional substance in a proportion less than that required under that section, is guilty of an offence.

Penalty: Imprisonment for 3 months.

(2) It is a defence to a charge for an offence against subsection (1) (other than the offence of supplying) if the person charged satisfies the court that the methylated spirits in respect of which he is charged was brought or imported by him into the Territory from a place where the additional substance is not required by the law in force in that place to be added to methylated spirits or to be added in the proportion required under section 60, as the case may be, and that it was in the Territory for so short a time before the alleged offence was committed that the addition to it of the prescribed substance was not practicable in that time.

Part XIII Offences, penalties, investigations, &c.

65 Use, &c., prohibited or subject to conditions

(1) Where the possession, use, production or manufacture in, or importation into, the Territory of a hazardous substance is prohibited under this Act, a person who possesses, uses, produces, manufactures or imports that hazardous substance in contravention of that prohibition is guilty of an offence.

Penalty: $10,000 or imprisonment for 5 years.

(2) Where the possession, use, production, manufacture, importation, supply or administration of a poison or hazardous substance is permitted by or under this Act subject to conditions, a person shall not possess, use produce, manufacture, import, supply or administer it except in accordance with those conditions.

Penalty: $2,000 or imprisonment for 2 years.

70A Food in poison containers

(1) A person shall not use a container as a container for food or drink where words indicating that the container is not to be used as a food container or the contents of the container are not to be taken are clearly and prominently embossed or clearly, prominently and indelibly written on it.

Penalty: $500.

(2) An offence of contravening subsection (1) is a regulatory offence.

71 Exemption

(1) Notwithstanding anything contained in this Act, a person who:

(a) is in possession of a poison which has been supplied to that person by or on the prescription of a medical practitioner, dentist or veterinary surgeon; or

(b) administers a poison to another person in accordance with the directions of a medical practitioner or a dentist,

is not guilty of an offence under this Act.

(2) In this section ***medical practitioner*** includes a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth.

78 Use of diamorphine hydrochloride

(1) The Chief Medical Officer may, subject to subsection (2), authorize:

(a) the possession;

(b) the production, preparation or manufacture;

(c) the supply to another person;

(d) the administering to another person; or

(e) the use,

of diamorphine hydrochloride and, notwithstanding anything contained elsewhere in this Act, a person so authorized may possess, produce, prepare, manufacture, supply, administer or use, as the case may be, that drug in accordance with that authorization.

(2) The Chief Medical Officer shall not authorize:

(a) the possession, production, preparation or manufacture of diamorphine hydrochloride unless for the purpose of treating a terminally ill person; or

(b) the supply to another person, the administering to another person or the use by a person of diamorphine hydrochloride unless he is satisfied that the person who is to use or to be treated with the drug is:

(i) terminally ill; and

(ii) suffering such pain that the use or administration of the drug is warranted in the circumstances.

(3) An authorization referred to in subsection (1) shall:

(a) be in writing;

(b) be signed by the Chief Medical Officer;

(c) name the person to whom the authorization is given; and

(d) where the authorization relates to the use or administration of diamorphine hydrochloride, name the person who is to use the drug or to whom it is to be administered.

81A Regulatory offences

An offence of contravening or failing to comply with section 11, 14, 17, 20, 25, 28, 29, 31, 34(3), 36, 39(4), 40, 43(2), 44, 45, 46, 47, 48, 49, 50, 52, 54(2) or 59 is a regulatory offence.

81B General penalty

A person who contravenes or fails to comply with a provision of this Act in respect of which no penalty, other than by this section, is provided, is guilty of an offence.

Penalty: $2,000 or imprisonment for 2 years.

86 Order of inspectors

A person ordered by an inspector to withdraw from supply a hazardous substance which is not packed or labelled in accordance with the requirements of this Act, the Regulations or the *Containers for Hazardous Substances Act* shall comply with that order.

Penalty: $200 or imprisonment for 3 months.

87 Obstruction of police or inspector

A person shall not obstruct or hinder a member of the Police Force or an inspector in the performance of his duties under, or the execution of the powers vested in him by, this Act.

Penalty: $500 or imprisonment for 6 months.

Part XIV Miscellaneous

89 Control of certain substances

The Minister may, by notice in the *Gazette*, prohibit:

(a) the possession or use in;

(b) the production or manufacture in; or

(c) the importation into,

the Territory of a poison or hazardous substance, or permit that possession, use, production, manufacture or importation subject to such conditions as to its transportation, storage, packaging, labelling, use or otherwise as he thinks fit.

90 Minister may amend schedules

(1) Subject to subsection (2), the Minister may, by notice in the *Gazette*, amend Schedule II, III, or IV or a schedule in Part B of the schedules to this Act.

(2) The Minister shall not amend a schedule referred to in subsection (1) unless he is satisfied that, by so doing, the schedule will comply with the recommendations for the time being of the National Health and Medical Research Council established by an order made under section 9 of the *National Health Act 1953* of the Common-wealth.

(3) A notice under subsection (1) shall take effect from the date of its notification in the *Gazette* or, where a later date is provided for in the notice, from the date so provided, and shall have effect as if it were an Act made by the Legislative Assembly.

91 Minister may prescribe fees

The Minister may, by notice in the *Gazette*, prescribe the fees payable in respect of a registration, licence, authorization and other forms of authority granted or issued under this Act.

91A Disclosure of information to medical practitioners

(1) The Chief Medical Officer may, as he thinks fit:

(a) maintain, and distribute from time to time to medical practitioners, a list of persons whom the Chief Medical Officer suspects, as a result of information obtained under this Act, of having an addiction to a substance to which this Act applies; or

(b) in response to a request by a medical practitioner in respect of a particular person, confirm whether the Chief Medical Officer suspects, as a result of information obtained under this Act, that the person has an addiction to a substance to which this Act applies.

(2) A medical practitioner shall not, except to another medical practitioner in the course of and for the purpose of the practise of medicine or with the approval of the Chief Medical Officer, disclose, directly or indirectly, to a person any information provided to the medical practitioner under this section.

(3) No action or proceedings, civil or criminal, shall be commenced or be continued against the Chief Medical Officer for or in relation to any thing done in good faith by the Chief Medical Officer in the exercise of his powers under this section.

92 Regulations

(1) The Administrator may make regulations, not inconsistent with this Act, prescribing all matters required or permitted by this Act to be prescribed, or necessary or convenient to be prescribed for carrying out or giving effect to this Act.

(2) Without limiting the generality of subsection (1), the Regulations may prescribe:

(a) the standards relating to, the precautions to be taken in, and the manner of, handling, transporting, packaging, labelling and disposal of poisons and hazardous substances; and

(b) penalties, not exceeding a fine of $2,000, for breaches of the Regulations.

The Schedules

Part A

SCHEDULE I – [Repealed]

SCHEDULE

PART A

SCHEDULE II

PROHIBITED DRUGS

POISONS WHICH ARE DRUGS OF ABUSE, THE MANUFACTURE, POSSESSION, SALE OR USE OF WHICH IS PROHIBITED EXCEPT FOR AMOUNTS WHICH MAY BE NECESSARY FOR MEDICAL OR SCIENTIFIC RESEARCH CONDUCTED WITH THE APPROVAL OF COMMONWEALTH AND/OR STATE OR TERRITORY HEALTH DEPARTMENTS. (TRIVIAL OR UNOFFICIAL NAMES ARE MARKED *)

ACETORPHINE
ACETYL-ALPHA-METHYLFENTANYL
ALPHA-METHYLFENTANYL
ALPHA-METHYLTHIOFENTANYL
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL) PHENYLPROPANE *(STP OR DOM)
BETA-HYDROXYFENTANYL
BETA-HYDROXY-3-METHYLFENTANYL
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA)
BUFOTENINE
CANNABIS
CATHINONE
DESOMORPHINE
N,N-DIETHYLTRYPTAMINE *(DET)
2,5-DIMETHOXYAMPHETAMINE *(DMA)
2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB)
2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE *(DOET)
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN)
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DHMP)
N,N-DIMETHYLTRYPTAMINE *(DMT)
ETICYCLIDINE *(PCE)
ETORPHINE
HARMALINE
HARMINE
HEROIN

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL)
4-HYDROXYBUTANOIC ACID
KETOBEMIDONE
LYSERGIDE
MESCALINE – see 3,4,5-trimethoxyphenylethylamine
METHAQUALONE
5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MMDA)
4-METHOXY-a-METHYLPHENYLETHYLAMINE *(PMA)
3,4-METHYLENEDIOXYAMPHETAMINE *(MDA)
3,4-METHYLENEDIOXY-N, a-DIMETHYLPHENYLETHYLAMINE *(MDMA)
3-METHYLFENTANYL
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP)
3-METHYLTHIOFENTANYL
MUSCIMOL
PARA-FLUOROFENTANYL
PHENCYCLIDINE *(PCP)
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP)
PSILOCINE – see 3-(2-dimethylaminoethyl)-4-hydroxyindole
PSILOCYBINE
PSILOTSIN – see 3-(2-dimethylaminoethyl)-4-hydroxyindole
ROLICYCLIDINE *(PHP or PCPY)
TENOCYCLIDINE *(TCP)
TETRAHYDROCANNABINOLS and their alkyl homologues **except** when separately specified in this Schedule
THIOFENTANYL
3,4,5-TRIMETHOXY-a-METHYLPHENYLETHYLAMINE *(TMA)
3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) and other substances structurally derived from methoxy-phenylethlamine **except**:

(a) methoxyphenamine; or

(b) where separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE

PART A

SCHEDULE IV

GENERAL EXEMPTIONS

CERAMICS
ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS and LAMPS
ELECTRONIC COMPONENTS
EXPLOSIVES
FOOD excluding food additives before incorporation into food
GLAZED POTTERY
LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents
MATCHES
MOTOR, HEATING and FURNACE FUELS, **except**:

(a) when the contrary intention appears in any Schedule;
(b) when containing methanol;
(c) toy or hobby fuels; or
(d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

PAPER **except**:

(a) when prepared for pesticidal use; or
(b) when containing a poison included in Schedule 8 or a Prohibited substance.

PHOTOGRAPHIC PAPER and FILM
PIGMENTS when immobilised in a polymer
PRINTING INKS and INK ADDITIVES **except** when containing:

(a) a pesticide; or
(b) an aromatic extract oil.

SINGLE-USE TUBES for the estimation of alcohol content of breath
TIMBER and WALLBOARD
VITREOUS ENAMELS
WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5

SPECIFIC EXEMPTIONS

ACETOFENATE
ACINITRAZOLE
AGROBACTERIUM RADIOBACTER
ALIPHATIC ALCOHOLS, (C^6-C10)
ALUM
ALUMINIUM SILICATE
ALUMINIUM tris (ETHYLPHOSPHONATE)
AMMONIUM CHLORIDE
AMMONIUM ETHYL CARBAMOYL PHOSPHONATE
AMMONIUM PHOSPHATE
AMMONIUM SULPHAMATE

AMMONIUM SULPHATE
AMMONIUM THIOSULPHATE
AMPROLIUM
AMYL ACETATE
AMYL ALCOHOL
AMYL LACTATE
ANDROSTENEDIONE ALBUMEN CONJUGATE with DEA DEXTRAN ADJUNCT
ANILAZINE
ANTHRAQUINONE
ARNICA
ASPARTIC ACID
ASUYLAM
ATRAZINE
AZIPROTRYNE
BACILLUS THURINGIENSIS
BENFLURALIN
BENSULFURON-METHYL
BENZOIC ACID
6-BENZLADENINE
BENZYL ALCOHOL
BENZYL BENZOATE
BETAINE HYDROCHLORIDE
BISACODYL
BITERTANOL
BIURET
BORO-TANNIC complex
BROMACIL
BROMOPROPYLATE
BUCARPOLATE
BUPIRIMATE
BUQUINOLATE
BUTADIENE FURFURAL COPOLYMER
BUTOPYRONOXYL
BUTOXYPOLYPROPYLENE GLYCOL
BUTRALIN
BUTYL ACETATE
BUTYL ALCOHOL
n-BUTYL BUTYRATE
BUTYL ETHERS
n-BUTYL LACTATE
BUTYROLACTONE
CALCIUM CARBIDE
CALCIUM CHLORIDE
CALCIUM OXIDE
CALCIUM POLYSULPHIDE
CAPRYLIC ACID DIETHYLAMIDE
CARBETAMIDE

CARBON MONOXIDE
CARBOXIN
CETYL ALCOHOL
CHLORANIFORMETHAN
CHLORANIL
CHLORBENSIDE
CHLORFENSULPHIDE
CHLORFLUAZURON
CHLORFLURENOL
CHLORHEXIDINE
CHLORIDAZON
CHLOROBENZENE
CHLORONEB
CHLOROXURON
CHLOROXYLENOLS
CHLORTHAL-DIMETHYL
CITRONELLA OIL
CLENPIRIN
CLIOXANIDE
COBALT NAPHTHENATE
COLOCYNTH
COPPER SALTS **except** copper sulphate
CULICINOMYCES CLAVOSPORUS
CYCLAMIC ACID
CYCLOHEXANE
CYCLOHEXANOL
CYCLOHEXANOL ACETATE
CYCLOHEXANONE
CYCLOPRATE
CYROMAZINE
DALAPON
DECOQUINATE
DECYL ALCOHOL
DERRIS DUST
DIACETONE ALCOHOL
DIAVERIDINE
DIBUTYLPHTHALATE
DICHLOBENIL
DIETHANOLAMINE
DIETHYL CARBONATE
DIETHYL KETONE
DIFLUFENICAN
DI-ISOBUTYL CARBINOL
DIKEGULAC-SODIUM
DIMETHAMETRYN
DIMETHICONE
DIMETHYL CYCLOHEXANOL
DIMETHYL ETHER

DIMETHYL PHTHALATE
3,5-DINITRO-O-TOLUAMIDE
DINSED
DIOCTYL SODIUM SULPHOSUCCINATE
DIPENTENE
DIPHENYLAMINE
DIPROPYLENE GLYCOL MONOMETHYL ETHER
DI-H-PROPYL ISO-CINCHOMERATE
DIURON
DODECANOL
Z-8-DODECENYL ACETATE
2,2-DPA
ETHIDIMURON
ETHOPABATE
ETHYL ACETATE
ETHYL ALCOHOL
ETHYL AMYL KETONE
ETHYL BUTYL ACETATE
ETHYL BUTYRATE
ETHYL-1-(2,4-DICHLOROPHENYL)-5-TRICHLOROMETHYL-(1H)-1,2,4 TRIAZOLE-3-CARBOXYLATE
ETHYL FORMATE
ETHYL HEXANEDIOL
2-ETHYL HEXANOL
ETHYLIDENE CHLORIDE
ETHYL LACTATE
ETHYL METHACRYLATE
ETHYL SILICATE
FEBANTEL
FENBENDAZOLE
FENFURAM
FENOXYCARB
FENURON
FERRIC SULPHATE
FLUOMETURON
FLUROXYPYR
FOSAMINE
[[[2-[(2-FURANYL-METHYLENE) AMINO] PHENYL] AMINO] THIOXOMETHYL]-CARBAMATE
FURFURAL
FURFURYL ALCOHOL
GIBBERELLIC ACID
D-GLUCURONOLACTONE
GLYCOPHENE
GLYODIN
HELIOTHIS NUCLEAR POLYHEDROSIS VIRUS
HEPTYL ALCOHOL
HEXACHLOROETHANE

HEXAFLURON
HEXANOL
HEXYL ACETATE
HEXYL ALCOHOLS
HEXYTHIAZOX
HYDROPRENE
2-HYDROXYETHYL-N-OCTYL SULPHIDE
HYDROXYPROPYL CELLULOSE, for ophthalmic use
IMAZAPYR
IMAZAQUIN
INDOLE-3-ACETIC ACID
INDOLE BUTYRIC ACID
IODISED OIL INJECTION
IODOFORM
IPRODIONE
ISOAMYL ACETATE
ISOBORNYL THIOCYANOACETATE
ISOPROPYL ALCOHOL
ISOPROPYL BENZOATE
KARBUTILATE
LACTIC ACID
LAURYL ALCOHOL
LEAD, METALLIC
LENACIL
LIME SULPHUR
LINURON
MALEIC HYDRAZIDE
MANGANESE NAPHTHENATE
MEGLUMINE IOTHALAMATE
MELATONIN
MENTHOL
MESITYL OXIDE
METHENAMINE HIPPURATE
METHOPRENE
3-METHOXY BUTANOL
METHYOXY HEXANONE
METHYL ACETATE
METHYL AMYL ALCOHOL
METHYL BENZOQUATE
METHYL CYCLOHEXANOL
METHYL CYCLOHEXANOL ACETATE
METHYL CYCLOHEXANONE
2-METHYLFUR-3-ANILIDE
METHYL p-HYDROXY BENZOATE
METHYL LACTATE
2-METHYL-2,4-PENTANEDIOL
METHYL POLYSILOXANE
METICHLORPINDOL

METOXURON
METSULFURON METHYL
MONOCHLORCARVACROL
MONOCHLOROBENZENE
MONETHANOLAMINE
MONURON
MORANTEL
NAPHTHYL ACETAMIDE
NAPROPAMIDE
NEBURON
NICARBAZINE
NISIN
NITRALIN
NITRILOTRIACETIC ACID
NITROMETHANE
NITROTHAL-ISOPROPYL
NITROVIN
NORFLURAZON
N-OCTYL-BICYCLOHEPTENE DICARBOXIMIDE
OCTYL ACETATES
OCTYL ALCOHOLS
OXABETRINIL for seed treatment
OXIBENDAZOLE
PANCRELIPASE
PELARGONIC ACID
PENTACHLORO-2-CHLOROMETHYLSULFONAMIDE DIPHENYLETHER
PENTANOCHLOR
PERMETHRIN
PHENMEDIPHAM
d-PHENOTHRIN
PHTHALTHRIN
PICLORAM
n-PICOLINE
PINENE
PINE OILS
PIPERAZINE
PIPERONYL BUTOXIDE
PIPROTOL
PIROCTONE
POLOXALENE
POLY (GNRF) OVALBUMIN
POTASSIUM ALUMINIUM SILICATE
PROCYMIDONE
PROPAZINE
PROPYL ACETATES
PROPYL ALCOHOLS
PROPYL-N[3-(DIMETHYLAMINO)PROPYL] CARBAMATE
PROPYLENE GLYCOL

2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER
PROPYL GALLATE
PROPYZAMIDE
PROTEIN HYDROLYSATE
PSEUDOMONAS FLUORESCENS
QUASSIA
RED SQUILL
ROBENIDINE
SACCHARIN
SEAWEED and unfractionated seaweed extracts
SIDURON
SIMAZINE
SOAP BARB
SODIUM IOTHALAMATE
SODIUM NITRATE
SUCRALFATE
SULPHATED POLYSACCHARIDES
SULPHOXIDE
SWERTINOGEN
TANNIC ACID
TEBUTHIURON
TERBACIL
TEREPHTHALIC ACID
TETRAHYDROFURAN
TETRAHYDROFURFURYL ACETATE
TETRAHYDROFURFURYL ALCOHOL
TETRASUL
THIABENDAZOLE
THIDIAZURON
THIOPHANATE
THIOPHANATE-METHYL
THIOXOLONE
TRIASULFURON
TRICLABENDAZOLE
(Z)-9-TRICOSENE
TRIETHANOLAMINE
TRIETHYLENE GLYCOL
TRIFLURALIN
TRIFORINE
UREA
VINCLOZOLIN
VINYL ETHER
VITAMIN K
XANTHOPHYLL
ZINC NAPHTHENATE

PART B

For the purposes of Part B, ***designated solvents*** means the following :

acetone
dimethylformamide
hydrocarbons, liquid
methanol when included in Schedule 5
methyl ethyl ketone
methyl isoamyl ketone
methyl isobutyl ketone
phenyl methyl ketone
styrene
tetrachloroethylene
1,1,1-trichloroethane

SCHEDULE 1

POISONS OF PLANT ORIGIN OF SUCH DANGER TO HEALTH AS TO WARRANT THEIR BEING AVAILABLE ONLY FROM MEDICAL PRACTITIONERS, PHARMACISTS OR VETERINARY SURGEONS.

ACONITE (Aconitum spp)
COMFREY (Symphytum spp) for human internal use being:
- (a) any preparation; or
- (b) any part of the dried plant.

CROTON OIL
SAVIN OIL
TANSY OIL

SCHEDULE 2

POISONS FOR THERAPEUTIC USE THAT SHOULD BE AVAILABLE TO THE PUBLIC ONLY FROM PHARMACIES; OR WHERE THERE IS NO PHARMACY SERVICE AVAILABLE, FROM PERSONS LICENCED TO SELL SCHEDULE 2 POISONS.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid, (CH3COOH) for therapeutic use
ALOXIPRIN
ANTAZOLINE in eye drops
ASPIRIN **except**:
- (a) when included in Schedule 4 or 6;
- (b) in individually wrapped powders or sachets of granules each containing 650 milligrams or less of aspirin as the only therapeutically active constituent other than an effervescent agent when enclosed in a primary pack that:
  - (i) contains not more than 12 such powders or sachets of granules;
  - (ii) is labelled with warning statement; WARNING – This medication may be dangerous when used in large amounts or for a long period: CAUTION – This preparation is for the relief of minor and temporary ailments and should be used

strictly as directed. Prolonged use without medical supervision could be harmful; or

(iii) includes in the directions for use, in capital letters not less than 1.5 mm in height, warning statements: Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever; and CAUTION – Do not give to children under 2 years of age except on doctor's advice.

(c) in tablets or capsules each containing 325 milligrams or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in containers with a child resistant closure;

(ii) in a primary pack containing not more than 25 tablets or capsules;

(iii) the primary pack is labelled with warning statements: WARNING – This medication may be dangerous when used in large amounts or for a long period; or CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful; and

(iv) includes in the directions for use, in capital letters not less than 1.5 mm in height, warning statements: Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever; and CAUTION – Do not give to children under 2 years of age except on doctor's advice.

ATROPINE (excluding atropine methonitrate):

(a) in preparations containing 0.25 per cent or less of atropine; or

(b) atropine sulphate, 0.6 mg tablets in packs of six, when labelled for treatment of organophosphorous poisoning.

BELLADONNA in preparations containing 0.25 per cent or less of the alkaloids of belladonna

BENZAMINE when included in:

(a) lozenges, pastilles, tablets or capsules each containing 30 mg or less of benzamine;

(b) suppositories or bougies each containing 200 mg or less of benzamine; or

(c) preparations for topical use, other than eye drops, containing 10 per cent or less of benzamine.

BENZOCAINE when included in:

(a) lozenges, pastilles, tablets or capsules each containing 30 mg or less of benzocaine;

(b) suppositories or bougies each containing 200 mg or less of benzocaine; or

(c) preparations for topical use, other than eye drops, containing 10 per cent or less of benzocaine.

BENZOYL PEROXIDE in preparations for external human therapeutic use containing 5 per cent or less of benzoyl peroxide

BENZYDAMINE in preparations for topical use containing 3 per cent or less of benzydamine

BROMHEXINE

BROMPHENIRAMINE in oral preparations when compounded with one or more of the following medicaments:

(a) an antitussive except codeine or dihydrocodeine;

(b) an expectorant; or

(c) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

BUCLIZINE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness

BUTYLAMINOBENZOATE when included in:

(a) lozenges, pastilles, tablets or capsules each containing 30 mg or less of butylaminobenzoate;

(b) suppositories or bougies each containing 200 mg or less of butylaminobenzoate; or

(c) preparations for topical use, other than eye drops, containing 10 per cent or less of butylaminobenzoate.

CARBARYL in preparations for external human therapeutic use containing 2 per cent or less of carbaryl

CARBENOXOLONE for topical oral use

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE in oral preparations when compounded with one or more of the following medicaments:

(a) an antitussive **except** codeine or dihydrocodeine;

(b) an expectorant; or

(c) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

CINNAMEDRINE

CLIOQUINOL and other halogenated derivatives of 8-hydroxy-quinoline for external human use

CODEINE when:

(a) compounded with aspirin, paracetamol or any one of their derivatives, and no other analgesic substance:

(i) in tablets or capsules each containing 10 mg or less of codeine when:

(A) packed in blister or strip packaging or in a container with a child resistant closure; and

(B) in a primary pack containing 25 or less dosage units; or

(ii) in individually wrapped powders each containing 10 mg or less of codeine when in a primary pack containing 25 or less dosage units; or

(b) compounded with one or more other therapeutically active substances:
  (i) in divided preparations each containing 10 mg or less of codeine; or
  (ii) in undivided preparations containing 0.25 per cent or less of codeine; and
(c) labelled with a recommended dose not exceeding 15 mg of codeine.

CREOSOTE derived from wood, for human therapeutic use, **except** in preparations containing 3 per cent or less of phenols included in this Schedule

DEXCHLORPHENIRAMINE in oral preparations when compounded with one or more of the following medicaments:
(a) an antitussive except codeine or dihydrocodeine;
(b) an expectorant; or
(c) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 30 mg or less of dextromethorphan per dosage unit and with a recommended dose not exceeding 30 mg of dextromethorphan; or
(b) in undivided preparations containing 0.3 per cent or less of dextromethorphan with a recommended dose not exceeding 30 mg of dextromethorphan.

DICOPHANE (DDT) in preparations for human therapeutic use

DICYCLOMINE in preparations containing 0.1 per cent or less of dicyclomine

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:
(a) containing 5 mg or less of dihydrocodeine per dosage unit;
(b) packed in blister or strip packaging or in a container with a child resistant closure;
(c) enclosed in primary packs containing 25 or less dosage units; and
(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness

DIMETHISOQUIN in preparations for topical use

DIPHEMANIL METHYLSULPHATE in preparations for topical use

DIPHENHYDRAMINE
(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b) in oral preparations when compounded with one or more of the following medicaments:
  (i) an antitussive except codeine or dihydrocodeine;
  (ii) an expectorant; or
  (iii) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

DIPHENYLPYRALINE in oral preparations when compounded with one or more of the following medicaments:

(a) an antitussive except codeine or dihydrocodeine;
(b) an expectorant; or
(c) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE in oral preparations when compounded with one or more of the following medicaments:

(a) an antitussive except codeine or dihydrocodeine;
(b) an expectorant; or
(c) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

EPHEDRINE for internal use for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances in preparations containing 30 mg or less of ephedrine per recommended dose, **except** in liquid preparations containing 10 mg or less of ephedrine per recommended dose

ERYTHRITYL TETRANITRATE for therapeutic use

ETAFEDRINE

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or
(b) in preparations containing 10 per cent or less of ether.

ETHOHEPTAZINE in preparations containing 1 per cent or less of ethoheptazine

ETHYLMORPHINE when:

(a) compounded with one or more other therapeutically active substances:
    (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
    (ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine; and
(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

FLUORIDES for human therapeutic use:

(a) sodium fluoride, in preparations for ingestion containing 2.2 mg or less of sodium fluoride per dosage unit; or
(b) in preparations for topical use **except**:
    (i) when included in Schedule 3;
    (ii) in dentifrices containing 1000 mg/kg or less of fluoride ion; or
    (iii) in other substances containing 15mg/kg or less of fluoride ion.

GELSEMIUM

GLUTARALDEHYDE for human therapeutic use

GLYCERYL TRINITRATE for therapeutic use **except** when included in Schedule 4

GUAIPHENESIN
- (a) in liquid preparations containig 2 per cent (200 mg/10 ml) or less of guaiphenesin; or
- (b) in divided preparations containing 120 mg or less of guaiphenesin per dosage unit.

HEXACHLOROPHANE in preparations for human skin cleansing purposes containing 3 per cent or less of hexachlorophane **except** in preparations for use on infants as specified in Schedule 4

HOMATROPINE in preparations containing 0.25 per cent or less of homatropine

HUMAN CHORIONIC GONADOTROPHIN or its antibody in pregnancy test kits

HYROQUINONE (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for external human therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except** hair preparations containing 1 per cent or less of hydroquinone

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances

HYOSCINE (excluding hyoscine butylbromide):
- (a) in preparations containing 0.25 per cent or less of hyoscine; or
- (b) in transdermal applicators containing 2 mg or less of hyoscine.

HYOSCYAMINE in preparations containing 0.25 per cent or less of hyoscyamine

HYOSCYAMUS in preparations containing 0.25 per cent or less of the alkaloids of hyoscyamus

IODINE
- (a) in preparations for internal human therapeutic use containing 300 mg or more of iodine except when labelled, "CAUTION – Total iodine intake may exceed recommended level when taking this preparation", and "WARNING – Contains iodine – do not take when pregnant except on physician's advice", written in letters not less than 1.5 mm in height; or
- (b) in preparations for external human therapeutic use containing more than 2.5 per cent of available iodine other than as iodine salts, derivatives or iodophors.

IRON COMPOUNDS for human internal use **except**:
- (a) when included in Schedule 4;
- (b) in divided preparations containing 5 mg or less of iron per dosage unit; or
- (c) in liquid oral preparations containing 0.1 per cent or less of iron.

ISOPROPAMIDE in preparations containing 2 per cent or less of isopropamide for dermal use

ISOSORBIDE DINITRATE for therapeutic use

LIGNOCAINE when included in:
- (a) lozenges, pastilles, tablets or capsules each containing 30 mg or less of lignocaine;

(b) suppositories or bougies each containing 200 mg or less of lignocaine; or
(c) preparations for topical use, other than eye drops, containing 10 per cent or less of lignocaine.

LINDANE in preparations for external human therapeutic use containing 2 per cent or less of lindane

LOBELIA **except** in preparations for smoking or burning:
(a) in divided preparations containing 2.5 mg or less of lobeline per dosage unit; or
(b) in undivided preparations containing 0.05 per cent or less of lobeline.

LOBELINE **except** in preparations for smoking or burning:
(a) in divided preparations containing 2.5 mg or less of lobeline per dosage unit; or
(b) in undivided preparations containing 0.05 per cent or less of lobeline.

LUTEINISING HORMONE or its antibody in human ovulation test kits

MALDISON in preparations for external human therapeutic use containing 2 per cent or less of maldison

MEBENDAZOLE for human therapeutic use

MERCURIC OXIDE in ointments for human ocular use

MERCURY ORGANIC COMPOUNDS for topical human therapeutic use, in preparations containing 0.5 per cent or less of mercury

METHOXAMINE **except** preparations for external use containing 1 per cent or less of methoxamine

METHOXYPHENAMINE

METHYLEPHEDRINE

MICONAZOLE for human use in topical preparations containing 2 per cent or less of miconazole, for the treatment of fungal infections of the skin

NAPHAZOLINE

NAPROXEN in packs of 12 or less tablets or capsules, for treatment of spasmodic dysmenorrhoea

NICLOSAMIDE for human therapeutic use

NITRATE ESTERS of polyhydric alcohols for therapeutic use **except** when separately specified in these Schedules

NOSCAPINE

OXETHAZAINE in preparations for internal use

OXYMETAZOLINE

PAPAVERINE **except** when included in Schedule 4

PARACETAMOL **except**:
(a) when included in Schedule 4;
(b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents, when:
(i) in a primary pack containing not more than 12 such powders or sachets;

(ii) labelled with warning statement WARNING – This medication may be dangerous when used in large amounts or for a long period; and CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful; and

(iii) not labelled for the treatment of children under 7 years of age;

(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents, when:

(i) packed in blister or strip packaging or in containers with child resistant closures;

(ii) in a primary pack containing not more than 25 such tablets or capsules;

(iii) labelled with warning statement WARNING – This medication may be dangerous when used in large amounts or for a long period; and CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful; and

(iv) not labelled for the treatment of children under 7 years of age.

PHEDRAZINE

PHENAZONE for external use

PHENIRAMINE

(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or

(b) in oral preparations when compounded with one or more of the following medicaments:

(i) an antitussive except codeine or dihydrocodeine;

(ii) an expectorant; or

(iii) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue of phenol boiling below 220 degrees celcius, for human therapeutic use, **except** in preparations containing 3 per cent or less of such substances

PHENYLENEDIAMINES and alkylated phenylenediamines for therapeutic use

PHENYLEPHRINE **except**:

(a) when included in Schedule 4;

(b) in preparations containing 0.5 per cent or less of phenylephrine; or

(c) in preparations for external use containing 1 per cent or less of phenylephrine.

PHOLCODINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholocodine; or

(b) in undivided preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine.

PODOPHYLLOTOXIN for external human therapeutic use in preparations containing 2 per cent or less of podophyllotixin

PODOPHYLLUM RESIN (podophyllin) for external human therapeutic use in preparations containing 10 per cent or less of podophyllin

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate

PRAMOXINE when included in preparations for external use, other than eye drops, containing 1 per cent or less of pramoxine

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use

PROMETHAZINE

(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or

(b) in oral preparations when compounded with one or more of the following medicaments:

(i) an antitussive except codeine or dihydrocodeine;

(ii) an expectorant; or

(iii) a sympathomimetic amine;

except in preparations for the treatment of children under 2 years of age.

PROPANTHELINE in preparations for topical use

PSEUDOEPHEDRINE **except** when included in Schedule 4:

(a) in preparations containing 60 mg or less of pseudoephedrine per recommended dose; or

(b) in slow-release preparations containing 120 mg or less of pseudoephedrine per recommended dose, for which approval of the slow-release characteristic has been granted by the Commonwealth Department of Community Services and Health.

PYRANTEL for human therapeutic use

PYRITHIONE ZINC for human therapeutic use, **except**:

(a) in semi-solid hair preparations; or

(b) in shampoos containing 2 per cent or less of pyrithione zinc when labelled with the statement, "Keep out of eyes" or "If in eyes rinse well with water".

SALICYLAMIDE **except** when included in Schedule 4

SILVER SALTS for therapeutic use, **except**:

(a) chewing tablets containing 5mg or less of silver per tablet; or

(b) solutions containing 0.3 per cent or less of silver.

SODIUM CROMOGLYCATE in nasal preparations for topical use

SODIUM NITRITE for therapeutic use

STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of staphisagria
STRAMONIUM in preparations containing 0.25 per cent or less of the alkaloids of stramonium, **except** in preparations for smoking or burning
TETRAHYDROZOLINE
THENYLDIAMINE
(a) in nasal preparations for topical use; or
(b) in oral preparations when compounded with one or more of the following medicaments:
(i) an antitussive except codeine or dihydrocodeine;
(ii) an expectorant; or
(iii) a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
TRAMAZOLINE
TRIMEPRAZINE in oral preparations when compounded with one or more of the following medicaments:
(a) an antitussive except codeine or dihyrocodeine;
(b) an expectorant; or
(c) a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
TRIPROLIDINE in oral preparations when compounded with one or more of the following medicaments:
(a) an antitussive except codeine or dihydrocodeine;
(b) an expectorant; or
(c) a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
TYMAZOLINE
XYLOMETAZOLINE

SCHEDULE 3

Poisons for therapeutic use that are dangerous or are so liable to abuse as to warrant their availability to the public being restricted to supply by pharmacists or medical, dental or veterinary practitioners.

ACEPIFYLLINE in liquid oral preparations
ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline
AMINOPHYLLINE in liquid oral preparations
ASTEMIZOLE as the only therapeutically active substance in divided preparations for oral use containing 10 mg or less of astemizole per dosage unit, in a pack containing 10 or less dosage units
AZATADINE in oral preparations
BENZOYL PEROXIDE in preparations containing 10 per cent or less of benzoyl peroxide for external human therapeutic use, **except** when included in Schedule 2
BROMPHENIRAMINE in oral preparations **except** when included in Schedule 2
BUCLIZINE in oral preparations **except** when included in Schedule 2

CHLOROFLUOROCARBONS alone or in combination with other propellants or refrigerants in liquified gas form for therapeutic use

CHLORPHENIRAMINE in oral preparations **except** when included in Schedule 2

CLEMASTINE in oral preparations

CLOTRIMAZOLE for human use in topical preparations containing 1 per cent or less of clotrimazole, for the treatment of fungal infections of the skin

CODEINE when compounded with aspirin, paracetamol or any one of their derivatives and no other analgesic substance, in divided preparations containing 10 mg or less of codeine per dosage unit and with a recommended dose not exceeding 15 mg of codeine, **except** when included in Schedule 2

CYPROHEPTADINE in oral preparations

DEXCHLORPHENIRAMINE in oral preparations **except** when included in Schedule 2

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine;

except when included in Schedule 2.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2

DIMETHINDENE in oral preparations

DIPHENHYDRAMINE in oral preparations **except** when included in Schedule 2

DIPHENYLPYRALINE in oral preparations **except** when included in Schedule 2

DITHRANOL for human therapeutic use

DOXYLAMINE in oral preparations **except** when included in Schedule 2

ECONAZOLE for human use in topical preparations containing 1 per cent or less of econazole for the treatment of fungal infections of the skin

EPHEDRINE for internal use, for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances **except**:

(a) when included in Schedule 2; or

(b) in liquid preparations containing 10 mg or less of ephedrine per recommended dose.

FENOTEROL in metered aerosols delivering 200 micrograms or less of fenoterol per metered dose

FLAVOXATE

FLUORIDES in dentifrices containing more than 1000 mg/kg of fluoride ion

FLUOROCARBONS alone or in combination with other propellants or refrigerants in liquified gas form for therapeutic use

FOLIC ACID for human therapeutic use **except** in preparations containing 500 micrograms or less of folic acid per recommended daily dose

FOLINIC ACID for human therapeutic use **except** in preparations containing 500 micrograms or less of folinic acid per recommended daily dose

HYDROCORTISONE (excluding its salts and derivatives other than hydrocortisone acetate) as the only therapeutically active substance in preparations for dermal use containing 0.5 per cent or less of hydrocortisone in packs containing 30 g or less where the labelling warns:

(a) against:
  (i) contact with the eyes; or
  (ii) use for acne; and
(b) against use, **except** on medical advice:
  (i) on children under 2 years of age;
  (ii) for more than 7 days; or
  (iii) under occlusive dressings.

IBUPROFEN as the only therapeutically active substance in divided preparations for oral use containing 200 mg or less of ibuprofen per dosage unit in a pack containing 50 or less dosage units labelled with a recommended daily dose of not more than 1200 mg of ibuprofen

IDOXURIDINE in preparations containing 0.5 per cent or less of idoxuridine for dermal use

INSULIN

ISOCONAZOLE for human use in topical preparations containing 1 per cent or less of isoconazole, for the treatment of fungal infections of the skin

LOPERAMIDE in packs of 8 dosage units or less, each dosage unit containing 2 mg or less of loperamide

MEFANAMIC ACID in packs of 30 or less capsules for treatment of spasmodic dysmenorrhoea

MEPYRAMINE in oral preparations

METHDILAZINE in oral preparations

MICONAZOLE for human use in topical preparations containing 2 per cent or less of miconazole for the treatment of oral candidiasis

NICOTINE in chewing tablets containing 2 mg or less of nicotine per tablet for use as an aid in withdrawal from tobacco smoking

NITROFURAZONE in preparations for dermal use containing 0.2 per cent or less of nitrofurazone

NYSTATIN in preparations for topical use for treatment of candidal infections only

PHENIRAMINE in oral preparations **except** when included in Schedule 2

PHENYLPROPANOLAMINE in preparations containing 25 mg or less of phenypropanolamine per recommended dose when labelled only for the relief of coughs or colds

PHENYLTOLOXAMINE in oral preparations

PODOPHYLLOTOXIN for external human therapeutic use in preparations containing 4 per cent or less of podophyllotoxin **except** when included in Schedule 2

PODOPHYLLUM RESIN (podophyllin) for external human therapeutic use in preparations containing 20 per cent or less of podophyllin **except** when included in Schedule 2

PROMETHAZINE in oral preparations **except** when included in Schedule 2
PSEUDOEPHEDRINE **except** when included in Schedule 2 or 4
QUININE for human internal therapeutic use **except** in liquids containing 40 mg/L or less of quinine
SALBUTAMOL
(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b) in capsules of dry powder for inhalation delivering 200 micrograms or less of salbutamol per dose.
SANTONIN
TERBUTALINE in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose
TERFENADINE as the only therapeutically active substance in divided preparations for oral use containing 60 mg or less of terfenadine per dosage unit in a pack containing 20 or less dosage units
THENYLDIAMINE in oral preparations **except** when included in Schedule 2
THEOPHYLLINE in liquid oral preparations
TIOCONAZOLE for human use in topical preparations containing 1 per cent or less of tioconazole, for the treatment of fungal infections of the skin
TRETINOIN for external human therapeutic use
TRIMEPRAZINE
(a) in solid oral preparations; or
(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 ml;
except when included in Schedule 2.
TRIPROLIDINE in oral preparations **except** when included in Schedule 2

SCHEDULE 4

POISONS THAT SHOULD, IN THE PUBLIC INTEREST, BE RESTRICTED TO MEDICAL, DENTAL OR VETERINARY PRESCRIPTION OR SUPPLY, TOGETHER WITH SUBSTANCES OR PREPARATIONS INTENDED FOR THERAPEUTIC USE, THE SAFETY OR EFFICACY OF WHICH REQUIRES FURTHER EVALUATION. (SUBSTANCES MARKED # ARE LISTED IN THE APPENDIX TO THIS SCHEDULE).

ACEBUTOLOL
ACEPIFYLLINE **except** when included in Schedule 3
ACEPROMAZINE
ACETANILIDE and alkyl acetanilides, for human therapeutic use
ACETAZOLAMIDE
ACETOHEXAMIDE
ACETYLCHOLINE
ACETYLCYSTEINE
ACETYLDIHYDROCODEINE when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of acetyldihydrocodeine.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
ACOKANTHERA SCHIMPERI for therapeutic use
ACTINOMYCIN D (Dactinomycin)
ACYCLOVIR
ADIPHENINE
ADONIS (Adonis vernalis) for therapeutic use
ADRENALINE **except**:

(a) when included in Schedule 3; or
(b) in preparations containing 0.02 per cent or less of adrenaline.

ALCLOMETASONE
ALCURONIUM SALTS
ALLOPURINOL
ALLYLOESTRENOL
ALPHADOLONE
ALPHAXALONE
ALPRAZOLAM
ALPRENOLOL
ALPROSTADIL
ALTRENOGEST
AMANTADINE
AMBENONIUM
AMBUCETAMIDE
AMBUTONIUM
AMETHOCAINE
AMIKACIN
AMILORIDE
3-AMINOBENZOIC ACID ETHYL ESTER METHANESULPHONATE
AMINOCAPROIC ACID
AMINOGLUTETHIMIDE
AMINOMETRADINE
AMINOPHENAZONE and derivatives therefrom for the treatment of animals
AMINOPHYLLINE **except** when included in Schedule 3
AMINOPTERIN
4-AMINOPYRIDINE for therapeutic use
AMINOREX
AMINOSALICYCLIC ACID
AMIODARONE
AMIPHENAZOLE
AMISOMETRADINE
AMITRIPTYLINE
AMODIAQUINE
AMOXYCILLIN
AMPHOMYCIN
AMPHOTERICIN
AMPICILLIN
AMSACRINE

AMYL NITRITE
AMYLOBARBITONE when packed and labelled for injection
AMYLOCAINE
ANABOLIC STEROIDAL AGENTS **except** when separately specified in these Schedules
ANGIOTENSIN AMIDE
ANTAZOLINE **except** when included in Schedule 2
ANTIBIOTICS **except**:
(a) when separately specified in these Schedules; or
(b) nisin.
ANTIGENS for human therapeutic use
ANTIHISTAMINES **except**:
(a) when included in Schedule 2 or 3; or
(b) when separately specified in this Schedule.
ANTIMONY ORGANIC COMPOUNDS for therapeutic use
APOCYNUM (Apocynum spp) for therapeutic use
APOMORPHINE
APROTININ
ASPIRIN
(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or
(b) for injection.
ASTEMIZOLE **except** when included in Schedule 3
ATENOLOL
ATRACURIUM BESYLATE
ATROPINE **except** when included in Schedule 2
AURANOFIN
AVOPARCIN **except**:
(a) when packed and labelled for use as an animal feed additive; or
(b) in animal feeds.
AZAPERONE
AZAPETINE
AZATADINE **except** when included in Schedule 3
AZLOCILLIN
AZTREONAM
BACAMPICILLIN
BACITRACIN **except**:
(a) when included in Schedule 6;
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.
BACLOFEN
BAMIPINE
BARBITURATES **except** when separately specified in these Schedules
BECLAMIDE
BELLADONNA **except** when included in Schedule 2
BEMEGRIDE

BENACTYZINE and other substances structurally derived from diphenylmethane with ataractic properties when used for therapeutic purposes
BENDROFLUAZIDE
BENORYLATE
BENSERAZIDE
BENZAMINE **except** when included in Schedule 2
BENZHEXOL
BENZILONIUM
BENZOCAINE **except** when included in Schedule 2
BENZODIAZEPINE derivatives **except** when separately specified in these Schedules
BENZOYL PEROXIDE in preparations for external human therapeutic use, **except** when included in Schedule 2 or 3
BENZPHETAMINE
BENZTROPINE
BENZYDAMINE **except** when included in Schedule 2
BENZYLPENICILLIN **except** when included in Schedule 6
BETAHISTINE
BETAXOLOL
BETHANECHOL CHLORIDE
BETHANIDINE
BIFONAZOLE
BIPERIDEN
BIMUTH COMPOUNDS for human therapeutic or cosmetic use, **except**:
- (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less;
- (b) bismuth oxychloride in cosmetics; or
- (c) bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BLEOMYCIN
BORON for human therapeutic use:
- (a) for internal use;
- (b) in glycerines or honeys of borax or boric acid;
- (c) in dusting powders for paediatric use; or
- (d) as a therapeutically active ingredient in other preparations for dermal use **except**:
  - (i) in antifungal preparations; or
  - (ii) in preparations containing 0.1 per cent or less of boron.

BRETYLIUM
BROMAZEPAM
BROMIDES, inorganic, for therapeutic use
BROMOCRIPTINE
BROMOFORM for therapeutic use
BROMPHENIRAMINE **except** when included in Schedule 2 or 3
BROMVALETONE
BUCLIZINE **except** when included in Schedule 2 or 3

BUFEXAMAC **except**:

(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or

(b) in suppositories.

BUMETANIDE
BUPIVACAINE
BUPRENORPHINE
BUSPIRONE
BUSULPHAN
BUTACAINE
BUTYLAMINOBENZOATE **except** when included in Schedule 2
BUTYLCHLORAL HYDRATE
BUTYL NITRITE
CALCITONIN
CALCITRIOL
CALCIUM CARBIMIDE for therapeutic use
CALOTROPIS (Calotropis spp) for therapeutic use
CAMPHORATED OIL excluding admixtures
CAMPHOTAMIDE
CANDICIDIN
CANINE TICK ANTI-SERUM
CANTHARIDIN
CAPREOMYCIN
CAPTODIAME
CAPTOPRIL
CAPURIDE
CARAMIPHEN
CARBACHOL
CARBAMAZEPINE
CARBARYL for human therapeutic use **except** when included in Schedule 2
CARBAZOCHROME
CARBENICILLIN
CARBENOXOLONE **except** when included in Schedule 2
CARBIDOPA
CARBIMAZOLE
CARBOCROMEN
CARBOPLATIN
CARBROMAL
CARINDACILLIN
CARMUSTINE
CARNIDAZOLE
CATALIN
CATHINE
CEFACLOR
CEFOPERAZONE
CEFOTAXIME
CEFOTETAN
CEFOXITIN

CEFTAZIDIME
CEFTRIAXONE
CEPHACETRILE
CEPHADROXIL
CEPHALEXIN
CEPHALORIDINE
CEPHALOTHIN
CEPHAMANDOLE
CEPHAPIRIN
CEPHAZOLIN
CEPHRADINE
CHENODEOXYCHOLIC ACID
CHLORAL FORMAMIDE
CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate
CHLORALOSE **except** when included in Schedule 6
CHLORAMBUCIL
CHLORAMPHENICOL
CHLORAZANIL
CHLORBUTOL in preparations for human oral use, **except** in preparations containing 0.5 per cent or less of chlorbutol as a preservative
CHLORCYCLIZINE
CHLORDIAZEPOXIDE
CHLORMERODRIN
CHLORMETHIAZOLE
CHLORMEZANONE
CHLOROFORM for use in anaesthesia
#2-(4-CHLOROPHENYL)-1,2,4-TRIAZOLE [5,1a]-ISOQUINOLINE for the treatment of animals
CHLOROQUINE
CHLOROTHIAZIDE
CHLORPHENIRAMINE **except** when included in Schedule 2 or 3
CHLORPHENTERMINE
CHLORPROMAZINE
CHLORPROPAMIDE
CHLORPROTHIXENE
CHLORTETRACYCLINE **except** when included in Schedule 6
CHLORTHALIDONE
CHLORZOXAZONE
CHOLESTYRAMINE for human therapeutic use
CHYMOPAPAIN, injection for human therapeutic use
CICLACILLIN
CILASTATIN
CIMETIDINE
CINCHOCAINE
CINOXACIN
CIPROFLOXACIN
CISAPRIDE

CISPLATIN
CLANOBUTIN
CLAVULANIC ACID
CLEMASTINE **except** when included in Schedule 3
CLEMIZOLE
CLENBUTEROL
CLIDINIUM
CLINDAMYCIN
CLOBAZAM
CLOBETASONE-17-BUTYRATE
CLOFENAMIDE
CLOFIBRATE
CLOMIPHENE
CLOMIPRAMINE
CLOMOCYCLINE
CLONAZEPAM
CLONIDINE
CLOPAMIDE
CLOPROSTENOL
CLORAZEPATE
CLOREXOLONE
CLORPRENALINE
CLOTRIMAZOLE **except** when included in Schedule 3 or 6
CLOXACILLIN
CLOZAPINE
CODEINE **except** when included in Schedule 2 or 3, when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 30mg or less of codeine per dosage unit; or
(b) in undivided preparations containing 1 per cent or less of codeine.
COLASPASE
COLCHICINE
COLESTIPOL for human therapeutic use
COLISTIN
CONVALLARIA (Convallaria spp) for therapeutic use
CORNILLA (Cornilla spp) for therapeutic use
CORTISONE and steroid suprarenal cortical hormones, **except** hydrocortisone in Schedule 3
CRYSTAL VIOLET for human therapeutic use
CURARE
CYCLANDELATE
CYCLIZINE
CYCLOFENIL
CYCLOPENTHIAZIDE
CYCLOPENTOLATE
CYCLOPHOSPHAMIDE
CYCLOPROPANE for therapeutic use
CYCLOSERINE

CYCLOSPORIN
CYCLOTHIAZIDE
CYCRIMINE
CYMARIN
CYPROHEPTADINE **except** when included in Schedule 3
CYPROTERONE
CYTARABINE
DACARBAZINE
DANAZOL
DANTROLENE
DAPSONE
DAUNORUBICIN
DEANOL
DEBRISOQUINE
DEMECARIUM BROMIDE
DEMECLOCYCLINE
DESIPRAMINE
DESLANOSIDE
DESMOPRESSIN (D.D.A.V.P.)
DETOMIDINE
DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3
DEXFENFLURAMINE
DEXTROMETHORPHAN **except** when included in Schedule 2
DEXTROPROPOXYPHENE
(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.
DEXTRORPHAN
DIAZEPAM
DIAZOXIDE
DIBENZEPIN
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)-AMINO) CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE (Sputolysin) **except** when in Schedule 6
DICHLORALPHENAZONE
DICHLORPHENAMIDE
DICLOFENAC
DICYCLAMINE **except** when included in Schedule 2
DIENOESTROL
DIETHAZINE
DIETHYLCARBAMAZINE for human therapeutic use
DIETHYLPROPION
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to at least 5 per cent of the dose of difenoxin
DIFLUNISAL
DIGITALIS LEAF for therapeutic use

DIGITOXIN
DIGOXIN
DIGOXIN ANTIBODY
DIHYDRALAZINE
DIHYDROCODEINE when compounded with one or more other medicaments:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine;

except when included in Schedule 2 or 3.
DIHYDROSTREPTOMYCIN **except** when included in Schedule 6
DIISOPROPYLAMINE DICHLOROACETATE
DILTIAZEM
DIMENHYDRINATE **except** when included in Schedule 2 or 3
DIMETHINDENE **except** when included in Schedule 3
DIMETHISOQUIN **except** when included in Schedule 2
DIMETHOXANATE
DIMETHYL SULPHOXIDE for therapeutic use **except**:

(a) when included in Schedule 6; or
(b) in in-vitro test kits.

DIMETRIDAZOLE
2,4-DINITROCHLOROBENZENE for therapeutic use
DINITROCRESOLS for therapeutic use
DINITRONAPHTHOLS for therapeutic use
DINITROPHENOLS for therapeutic use
DINITROTHYMOLS for therapeutic use
DINOPROST
DIPERODON
DIPHEMANIL METHYLSULPHATE **except** when included in Schedule 2
DIPHENHYDRAMINE **except** when included in Schedule 2 or 3
DIPHENIDOL
DIPHENOXYLATE in preparations containing per dosage unit 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to at least 1 per cent of the dose of diphenoxylate
DIPHENYLPYRALINE **except** when included in Schedule 2 or 3
DIPIVEFRIN
DIPYRIDAMOLE
DISOPHENOL
DISOPYRAMIDE
DISTIGMINE
DISULFIRAM for therapeutic use
DITHIAZANINE **except** when included in Schedule 6
DOBUTAMINE
DOMPERIDONE
DOPAMINE
DOTHIEPIN
DOXAPRAM

DOXEPIN
DOXORUBICIN
DOXYCYCLINE
DOXYLAMINE **except** when included in Schedule 2 or 3
DROPERIDOL
DROSTANOLONE
DYDROGESTERONE
ECONAZOLE **except** when included in Schedule 3 or 6
EDETIC ACID for human therapeutic use in preparations for injection or infusion
EMETINE **except** in preparations containing 0.2 per cent or less of emetine
ENALAPRIL
ENFLURANE for therapeutic use
EPHEDRINE **except**:

(a) when included in Schedule 2 or 3;
(b) in preparations for topical use containing 1 per cent or less of ephedrine; or
(c) for internal use for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances in liquid preparations containing 10 mg or less of ephedrine per recommended dose.

EPICILLIN
EPIRUBICIN
ERGOMETRINE
ERGOT
ERYSIMUM (Erysimum canescens) for therapeutic use
ERYTHROMYCIN **except**:

(a) when included in Schedule 6;
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

ESTRAMUSTINE
ETHACRYNIC ACID
ETHAMBUTOL
ETHAMIVAN
ETHCHLORVYNOL
ETHER for use in anaesthesia
ETHINAMATE
ETHINYLOESTRADIOL
ETHOGLUCID
ETHOHEPTAZINE **except** when included in Schedule 2
ETHOPROPAZINE
ETHOSUXIMIDE
ETHOTOIN
ETHOXZOLAMIDE
ETHYL CHLORIDE for inhalation anaesthesia

ETHYLMORPHINE when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;
except when included in Schedule 2.
ETHYLOESTRENOL
ETHYNODIOL
ETIDOCAINE
ETIDRONATE **except** in tooth pastes and gels containing 1 per cent or less of etidronate
ETILEFRIN HYDROCHLORIDE
ETOPOSIDE
ETRETINATE
FAMOTIDINE
FELODIPINE
FELYPRESSIN
FENCAMFAMIN
FENFLURAMINE
FENOPROFEN
FENOTEROL **except** when included in Schedule 3
FENPIPRAMIDE
FENPIPRANE
FENPROPOREX
FENPROSTALENE
FILGRASTIM
FLAVOPHOSPHOLIPOL **except**:
(a) when included in Schedule 6; or
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
FLECAINIDE
FLUCLOXACILLIN
FLUCYTOSINE
FLUFENAMIC ACID
FLUMAZANIL
FLUNISOLIDE
FLUNITRAZEPAM
FLUNIXIN MEGLUMINE
FLUORIDES in preparations for human ingestion **except** when included in Schedule 2 or 3
FLUOROURACIL
FLUOXETINE
FLUOXYMESTERONE
FLUPHENAZINE
FLUPROSTENOL
FLURAZEPAM
FLUROXENE for inhalation anaesthesia
FLUSPIRILENE

FOLLICLE-STIMULATING HORMONE (Animal)
FOSFESTROL
FRAMYCETIN
FRUSEMIDE
FUSIDIC ACID
GALANTHAMINE
GALANTHUS (Galanthus nivalis) for therapeutic use
GALLAMINE
GEMEPROST
GENTAMICIN
GLIBENCLAMIDE
GLIBORNURIDE
GLICLAZIDE
GLIPIZIDE
GLUCAGON
GLUTETHIMIDE
GLYCERYL TRINITRATE in preparations for injection
GLYCOPYRROLATE
GLYMIDINE
GONADORELIN
GONADOTROPHINS **except** when separately specified in this Schedule or in Schedule 2
GOSERELIN ACETATE
GRAMICIDIN
GRISEOFULVIN
GROWTH HORMONE
GUAIPHENESIN **except** when included in Schedule 2
GUANABENZ
GUANACLINE
GUANETHIDINE
HALCINONIDE
HALOPERIDOL and other substances structurally derived from butyrophenone with ataractic properties when used for therapeutic purposes, except when separately specified in this Schedule
HALOTHANE for therapeutic use
HEMEROCALLIS (Hemerocallis flava) for therapeutic use
HEPARIN for internal therapeutic use
HETACILLIN
HEXACHLOROPHANE
(a) in preparations for use on infants; or
(b) in other preparations **except** when included in Schedule 2 or 6.
HEXAMETHONIUM
HEXOCYCLIUM
HOMATROPINE **except** when included in Schedule 2
HYALURONIC ACID in preparations for injection
HYDRALAZINE
HYDROCHLOROTHIAZIDE
HYDROCYANIC ACID for therapeutic use

HYDROFLUMETHIAZIDE
HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:
(a) when included in Schedule 2; or
(b) in hair preparations containing 1 per cent or less of hydroquinone.
HYDROXYCHLOROQUINE
HYDROXYEPHEDRINE
HYDROXYPROGESTERONE
HYDROXYUREA
HYDROXYZINE
HYGROMYCIN **except**:
(a) when included in Schedule 6; or
(b) in preparations in concentrations of 50 mg/kg or less of antibiotic substances.
HYOSCINE **except** when included in Schedule 2
HYOSCYAMINE **except** when included in Schedule 2
HYOSCYAMUS **except** when included in Schedule 2
HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule
IBUFENAC
IBUPROFEN **except** when included in Schedule 3
IDOXURIDINE **except** when included in Schedule 3
IMIPENEM
IMIPRAMINE
INDAPAMIDE
INDOMETHACIN
INOSITOL NICOTINATE for internal use
INTERFERON
ION-EXCHANGE RESINS, anionic and cationic, for internal use in humans **except** when separately specified in this Schedule
IOPAMIDOL
IPRATROPIUM
IPRONIAZID
IRON compounds in injectable preparations for human therapeutic use
ISOAMINILE
ISOBUTYL NITRITE
ISOCARBOXAZID
ISOCONAZOLE **except** when included in Schedule 3 or 6
ISOETHARINE
ISOFLURANE for therapeutic use
ISOMETHEPTENE
ISONIAZID
ISOPRENALINE
ISOPROPAMIDE **except** when included in Schedule 2
ISOTRETINOIN
ISOXUPRINE
IVERMECTIN for use in dogs

KANAMYCIN
KETAMINE
KETOCONAZOLE
KETOPROFEN
KHELLIN
KITASAMYCIN **except**:
(a) when included in Schedule 6; or
(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL
LANATOCIDE C
LATAMOXEF
LAUDEXIUM METHYLSULPHATE
LEAD COMPOUNDS for human therapeutic use
LEFETAMINE
LEPTAZOL
LEUPRORELIN
LEVALLORPHAN
LEVAMISOLE
(a) for human therapeutic use; or
(b) in preparations for the prevention or treatment of heartworm in dogs.
LEVODOPA
LEVONORGESTREL
LIDOFLAZINE
LIGNOCAINE **except** when included in Schedule 2
LINCOMYCIN
LINDANE for human therapeutic use **except** when included in Schedule 2
LIOTHYRONINE SODIUM (Triiodothyronine)
LITHIUM salts for therapeutic use, **except** in preparations containing 0.01 per cent or less of lithium
LOBELIA **except**:
(a) when included in Schedule 2; or
(b) in preparations for smoking or burning.
LOBELINE **except** :
(a) when included in Schedule 2; or
(b) in preparations for smoking or burning.
LOMUSTINE
LOPERAMIDE **except** when included in Schedule 3
LORAZEPAM
LOXAPINE
LUTEINISING HORMONE
LYMECYCLINE
MAFENIDE **except** when included in Schedule 6
MALDISON for human therapeutic use **except** when included in Schedule 2
MAPROTILINE
MAZINDOL
MEBEVERINE

MEBHYDROLIN
MECAMYLAMINE
MECLOFENOXATE
MECLOZINE
MEDAZEPAM
MEDIGOXIN
MEDROXYPROGESTERONE
MEFENAMIC ACID **except** when included in Schedule 3
MEFENOREX
MEFLOQUINE
MEFRUSIDE
MEGESTROL
MELPHALAN
MEPACRINE
MEPENZOLATE
MEPHENESIN
MEPHENTERMINE
MEPIVACAINE
MEPROBAMATE
MEPYRAMINE **except** when included in Schedule 3
MERCAPTOPURINE
MERCURY for therapeutic use **except** when included in Schedule 2 or 6
MESALAZINE
MESTEROLONE
MESTRANOL
METARAMINOL
METERGOLINE
METFORMIN
METHACYCLINE
METHANDIENONE
METHANDRIOL
METHANTHELINIUM
METHAZOLAMIDE
METHDILAZINE **except** when included in Schedule 3
METHENOLONE
METHICILLIN
METHIMAZOLE
METHIXENE
METHOCARBAMOL
METHOTREXATE
METHOXSALEN
METHOXYFLURANE for therapeutic use
METHSUXIMIDE
METHYCLOTHIAZIDE
METHYLANDROSTANOLONE
METHYLDOPA
METHYLPENTYNOL and other substituted alkynes for internal use
METHYLTESTOSTERONE

METHYPRYLONE
METHYSERGIDE
METOCLOPRAMIDE
METOLAZONE
METOPROLOL
METRIZAMIDE
METRONIDAZOLE including benzoylmetronidazole
METYRAPONE
MEXILETINE
MEZLOCILLIN
MIANSERIN
MIBOLERONE
MICONAZOLE **except** when included in Schedule 2, 3 or 6
MIDAZOLAM
MINOCYCLINE
MINOXIDIL
MISOPROSTOL
MITHRAMYCIN
MITOBRONITOL
MITOMYCIN
MITOZANTRONE
MONENSIN **except**:

(a) when included in Schedule 6; or
(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE or other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use
MONOCLONAL ANTIBODIES for therapeutic use **except** in diagnostic test kits
MOPERONE
MUPIROCIN
MUSTINE
NADOLOL
NALBUPHINE
NALIDIXIC ACID **except** when included in Schedule 6
NALORPHINE
NALOXONE
NANDROLONE
NAPROXEN **except** when included in Schedule 2
NARASIN **except**:

(a) when included in Schedule 6; or
(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NATAMYCIN
NEOMYCIN **except** when included in Schedule 6
NEOSTIGMINE
NETILMICIN

NICOCODINE when compounded with one or more other medicaments:
- (a) in divided preparations containing not more than 100 mg of nicocodine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of nicocodine.

NICODICODINE when compounded with one or more other medicaments:
- (a) in divided preparations containing not more than 100 mg of nicodicodine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of nicodicodine.

NICOTINE in chewing tablets containing 4 mg or less of nicotine per tablet for use as an aid in withdrawal from tobacco smoking **except** when included in Schedule 3

NICOTINIC ACID for human therapeutic use **except**:
- (a) in preparations containing 50 mg or less of nicotinic acid per recommended daily dose; or
- (b) nicotinamide.

NICOTINYL ALCOHOL for internal use

NICOUMALONE for internal therapeutic use

NIFEDIPINE

NIFENAZONE

NIKETHAMIDE

NIRIDAZOLE

NITRAZEPAM

NITROFURAN and its derivatives for human therapeutic use **except** when included in Schedule 3

NITROUS OXIDE for therapeutic use

NIZATADINE

NOMIFENSINE

NORADRENALINE (excluding its derivatives)

NORCODEINE when compounded with one or more other medicaments:
- (a) in divided preparations containing not more than 100mg of norcodeine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of norcodeine.

NORETHANDROLONE

NORETHISTERONE

NORFLOXACIN

NORTRIPTYLINE

NOVOBIOCIN **except** when included in Schedule 6

NYSTATIN **except** when included in Schedule 3

OCTAMYLAMINE

OCTATROPINE

OCTREOTIDE

OCTYL NITRITE

OESTRADIOL **except** when included in Schedule 6

OESTRIOL

OESTRONE

OLEANDER (Nerium oleander) for therapeutic use
OLEANDOMYCIN **except**:
(a) when included in Schedule 6; or
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLEANDRIN
OLSALASINE SODIUM
OMEPRAZOLE
OPIPRAMOL
ORCIPRENALINE
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:
(a) when included in Schedule 2; or
(b) when separately specified in this Schedule.
ORNIDAZOLE
ORNIPRESSIN
ORPHENADRINE
ORTHOCAINE
ORTHOPTERIN
OUABAIN
OXACILLIN
OXANDROLONE
OXAZEPAM
OXICONAZOLE
OXOLAMINE
OXPENTIFYLLINE
OXPRENOLOL
OXYBUPROCAINE
OXYMESTERONE
OXYMETHOLONE
OXYPHENBUTAZONE
OXYPHENCYCLIMINE
OXYPHENONIUM
OXYTETRACYCLINE **except** when included in Schedule 6
OXYTOCIN
PAMAQUINE
PANCURONIUM BROMIDE
PAPAVERINE for injection
PARACETAMOL when combined with aspirin, caffeine or salicylamide or any derivative of these substances
PARALDEHYDE
PAROMOMYCIN
PEMOLINE
PEMPIDINE
PENICILLAMINE
PENTAMETHONIUM
PENTAMIDINE ISETHIONATE
PENTHIENATE

PENTOBARBITONE when packed and labelled for injection
PENTOLINIUM
PERHEXILENE
PERICYAZINE
PERPHENAZINE
PHENACEMIDE
PHENACETIN for therapeutic use
PHENAZONE **except** when included in Schedule 2
PHENAZOPYRIDINE
PHENELZINE
PHENETHICILLIN **except** when included in Schedule 6
PHENFORMIN
PHENGLUTARIMIDE
PHENINDIONE for internal therapeutic use
PHENIRAMINE **except** when included in Schedule 2 or 3
PHENOXYBENZAMINE
PHENOXYMETHYLPENICILLIN **except** when included in Schedule 6
PHENSUXIMIDE
#PHENTERMINE
PHENTHIMENTONIUM
PHENTOLAMINE
PHENYAPIN
PHENYLBUTAZONE
PHENYLEPHRINE in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine
PHENYLPROPANOLAMINE **except** when included in Schedule 3
PHENYLTOLOXAMINE **except** when included in Schedule 3
PHENYTOIN
PHOLCODINE when compounded with one or more other medicaments:

(a) in divided preparations containing not more than 100 mg of pholcodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of pholcodine;

except when included in Schedule 2.
PHYSOSTIGMINE
PICROTOXIN
PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine
PIMOZIDE
PINDOLOL
PIPENZOLATE
PIPERACILLIN
PIPERIDOLATE
PIPOBROMAN
PIPRADROL
PIRENZEPINE
PIROXICAM

PITUITARY, its extracts and active principles or their synthetic substitutes **except** when separately specified in this Schedule
PIZOTIFEN
PODOPHYLLOTOXIN for human therapeutic use **except** when included in Schedule 2 or 3
PODOPHYLLUM RESIN (podophyllin) for human therapeutic use **except** when included in Schedule 2 or 3
POLYESTRADIOL
POLYMETHYLENE BISTRIMETHYL AMMONIUM COMPOUNDS
POLYMYXIN
POLYSULPHATED GLYCOSAMINOGLYCANS in preparations for injection, **except** where otherwise specified in this Schedule
POTASSIUM PERCHLORATE for therapeutic use
PRACTOLOL
PRAMOXINE **except** when included in Schedule 2
PRAZEPAM
PRAZIQUANTEL for human therapeutic use
PRAZOSIN
PREGNENOLONE ACETATE **except** in preparations for topical use
PRENYLAMINE
PRILOCAINE
PRIMAQUINE
PRIMIDONE
PROBENECID
PROBUCOL
PROCAINAMIDE
PROCAINE
PROCAINE PENICILLIN **except** when included in Schedule 6
PROCARBAZINE
PROCHLORPERAZINE
PROCYCLIDINE **except** when included in Schedule 2
PROGESTERONE **except** when included in Schedule 6
PROGUANIL
PROLINTANE
PROMAZINE
PROMETHAZINE **except** when included in Schedule 2 or 3
PROPANIDID
PROPANTHELINE **except** when included in Schedule 2
PROPOFOL
PROPOXUR for human therapeutic use
PROPRANOLOL
PROPYLHEXEDRINE
PROPYLTHIOURACIL
PROPYPHENAZONE
PROQUAZONE
PROSTAGLANDINS **except** where separately specified in this Schedule
PROSTIANOL
PROTHIONAMIDE

PROTIRELIN (thyrotrophin releasing factor)
PROTRIPTYLINE
PROXYMETACAINE
PSEUDOEPHERINE in preparations for stimulant, appetite suppression or weight control purposes
PYRAZINAMIDE
PYRIDOSTIGMINE
PYRIDOXINE HYDROCHLORIDE in preparations for human use containing more than 50mg of pyridoxine per recommended daily dose unless labelled with the warning statement "Warning – this medication may be dangerous when used in large amounts or for a long time", or
Warning – this product contains pyridoxine hydrochloride which may be dangerous when used in large amounts or for a long time:
PYRIMETHAMINE
PYROVALERONE
QUINETHAZONE
QUINIDINE
RANITIDINE
RAUWOLFIA SERPENTINA
RIBAVIRIN
RIFAMPICIN
RIMITEROL HYDROBROMIDE
RITODRINE
ROLITETRACYCLINE
ROMIFIDINE
ROSOXACIN
SALBUTAMOL **except** when included in Schedule 3
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances
SALINOMYCIN **except**:
(a) when included in Schedule 6; or
(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.
SELENIUM for therapeutic use **except**:
(a) when included in Schedule 5, 6 or 7;
(b) as elemental selenium, in pellets containing 50 mg/kg or less of selenium, for the treatment of animals;
(c) in tablets, for the treatment of animals, each:
(i) weighing 2g or more; and
(ii) containing 30 micrograms or less of selenium; or
(d) in animal feeds containing 0.1 g/tonne or less of selenium.
SEMISODIUM VALPROATE
SERMORELIN
SERA for human therapeutic use
SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules
SILVER SULPHADIAZINE
SISOMYCIN

SODIUM CELLULOSE PHOSPHATE for human internal use
SODIUM CROMOGLYCATE **except** when included in Schedule 2
SODIUM NITROPRUSSIDE for human therapeutic use
SODIUM PENTOSAN POLYSULPHATE
SODIUM VALPROATE
SOLASODINE
SONTOQUINE
SOTALOL
SPARTEINE
SPECTINOMYCIN
SPIRAMYCIN **except**:
- (a) when included in Schedule 6; or
- (b) in animal feeds for growth promotion in pigs or poultry containing 50 mg/kg or less of antibiotic substances.

SPIRONOLACTONE
STANOLONE
STANOZOLOL
STILBOESTROL
STRAMONIUM **except**:
- (a) when included in Schedule 2; or
- (b) in preparations for smoking or burning.

STREPTOMYCIN **except** when included in Schedule 6
STROPHANTHIN-K
STROPHANTHUS (Strophanthus spp) for therapeutic use
STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals
SULFADOXINE
SULPHAMETROLE
SULINDAC
SULPHONAMIDES **except**:
- (a) when separately specified in this Schedule;
- (b) when included in Schedule 6;
- (c) sulphaquinoxaline when incorporated in:
  - (i) baits for the destruction of vermin; or
  - (ii) animal feeds containing 200 mg/kg or less of sulphaquinoxaline; or
- (d) oryzalin.

SULPHATROXAZOLE
SULPHINPYRAZONE
SULPHOMYXIN
SULPHONAL and alkyl sulphonals
SULTHIAME
SUMATRIPTAN
SUXAMETHONIUM SALTS
TACRINE
TAMOXIFEN
TEMAZEPAM
TENIPOSIDE

TENOXICAM
TERBUTALINE **except** when included in Schedule 3
TERFENADINE **except** when included in Schedule 3
TEROPTERIN
TESTOSTERONE **except** when included in Schedule 6
TETRABENAZINE
TETRACOSACTRIN
TETRACYCLINE **except** when included in Schedule 6
THALIDOMIDE
THENYLDIAMINE **except** when included in Schedule 2 or 3
THEOPHYLLINE **except** when included in Schedule 3
THEVETIA (Thevetia neriifolia) for therapeutic use
THEVETIN
THIACETARSAMIDE, in preparations for the prevention or treatment of heart worm in dogs
THIACETAZONE
THIAMBUTOSINE
THIAZOSULPHONE
THIETHYLPERAZINE
THIOGUANINE
THIOPROPAZATE
THIORIDAZINE
THIOTEPA
THIOTHIXENE
THIOURACIL
THIOUREA for therapeutic use
THYROID **except** when separately specified in this Schedule
THYROTROPHINE (T.S.H.)
THYROXINE SODIUM
TIAMULIN **except**:
(a) when included in Schedule 6; or
(b) in prepared animal feeds.
TICARCILLIN
TIEMONIUM
TIGLOIDINE
TILETAMINE
TIMOLOL
TINIDAZOLE
TIOCONAZOLE **except** when in Schedule 3
TIPEPIDINE
TOBRAMYCIN
TOCAINIDE
TOLAZAMIDE
TOLAZOLINE for internal use
TOLBUTAMIDE
TOLPROPAMINE
TOXOIDS for human therapeutic use
TRANEXAMIC ACID

TRANYLCYPROMINE
TRETAMINE
TRIAMTERENE
TRIAZIQUONE
TRIAZOLAM
TRICHLOROETHYLENE for therapeutic use
TRICLOFOS
TRICYCLAMOL
TRIDIHEXETHYL
TRIFLUOPERAZINE
TRIFLUPERIDOL
TRIMEPRAZINE **except** when included in Schedule 2 to 3
TRIMETAPHAN
TRIMETHOPRIM
TRIMIPRAMINE
TRIMUSTINE
TRIOXYSALEN
TRIPELENNAMINE
TRIPROLIDINE **except** when included in Schedule 2 or 3
TROPICAMIDE
TROXIDONE
TUBOCURARINE
TULOBUTEROL
TYLOSIN **except**:

(a) when included in Schedule 6;
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

URETHANE (excluding its derivatives) for therapeutic use
UROFOLLITROPHIN (human follicle – stimulating hormone)
VACCINES for human therapeutic use
VACCINES, veterinary live virus **except**:

(a) poultry vaccines;
(b) pigeon pox vaccine; or
(c) scabby mouth vaccine.

VALNOCTAMIDE
VANCOMYCIN
VASOPRESSIN
VECURONIUM BROMIDE
VERAPAMIL
VERATRUM
VIDARABINE
VINBLASTINE
VINCRISTINE
VINDESINE
VIPRYNIUM

VIRGINIAMYCIN **except**:
- (a) when included in Schedule 6; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

VISNADINE
VITAMIN A for human therapeutic use, **except** in preparations containing 10 000 I.U. or less of vitamin A per recommended daily dosage
VITAMIN D for human therapeutic use **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dosage
WARFARIN for internal therapeutic use
XANTHINOL NICOTINATE
XYLAZINE
YOHIMBINE
ZERANOL **except** when included in Schedule 6
ZIDOVUDINE
ZINC COMPOUNDS for human internal use **except**:
- (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
- (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when labelled with the statement "WARNING: May be dangerous if taken in large amounts or for a long period" or "WARNING: Contains zinc, which may be dangerous if taken in large amounts or for a long period.

ZOLAZEPAM

APPENDIX TO SCHEDULE 4

POISONS INCLUDED IN SCHEDULE 4 OR 8 FOR WHICH ADDITIONAL CONTROLS ON POSSESSION AND/OR SUPPLY SHOULD BE IMPOSED BY STATE/TERRITORY REGULATION. CONTROLS MAY RELATE TO POSSESSION, RECORDING, DESTRUCTION, PRESCRIBING AND DISPENSING.

PART I

DRUGS TO BE AVAILABLE ONLY FROM, OR ON PRESCRIPTION OF, OR USED BY, PERSONS OR CLASSES OF PERSONS SPECIFICALLY AUTHORISED.

CLOMIPHENE for human use for the stimulation of ovulation
Available only on the prescription or order of an authorised medical practitioner
CYCLOFENIL for human use for the stimulation of ovulation
Available only on the prescription or order of an authorised medical practitioner
DINOPROST for human use
Available only on the prescription or order of an authorised medical practitioner

ETRETINATE for human use

Available only on the prescription or order of a specialist physician or a dermatologist

1. The supplier to provide the patient or his/her agent with an appropriate patient information leaflet.
2. The product as dispensed must carry the warning statement "WARNING – CAUSES BIRTH DEFECTS".
3. The prescriber should ensure that the possibility of pregnancy has been excluded prior to the commencmment of treatment and that the patient be informed that she must not become pregnant for a period of 24 months after completion of treatment.

ISOTRETINOIN for human use

Available only on the prescription or order of a specialist physician or a dermatologist

1. The supplier to provide the patient or his/her agent with an appropriate patient information leaflet.
2. The product as dispensed must carry the warning statement "WARNING – CAUSES BIRTH DEFECTS".
3. The prescriber should ensure that the possibility of pregnancy has been excluded prior to the commencement of treatment and that the patient is informed that she must not become pregnant for a period of 1 month after completion of treatment.

LUTEINISING HORMONE for human use

Available only on the prescription or order of an authorised medical practitioner

THALIDOMIDE for human use

Available only on the prescription or order of a specialist physician or a dermatologist.

1. The supplier to provide the patient or his/her agent with an appropriate patient information leaflet.
2. The product as dispensed must carry the warning statement "WARNING – CAUSES BIRTH DEFECTS".
3. The prescriber should ensure that the possibility of pregnancy has been excluded prior to the commencement of treatment and that the patient is informed that she must not become pregnant for a period of 1 month after completion of treatment.

UROFOLLITROPHIN (HUMAN FOLLICLE-STIMULATING HORMONE) for human use

Available only on the prescription or order of an authorised medical practitioner

PART II

DRUGS REQUIRING ADDITIONAL CONTROLS

4-AMINOPYRIDINE
: Available only for the treatment of animals

ANTIBIOTICS
: Antibiotics for intramammary infusion should be suitably coloured with at least 25mg of Brilliant Blue FCF or other approved colour so that the visual endpoint excludes 95 per cent of excreted antibiotic

BUPRENORPHINE
: Supply of this drug is subject to monitoring. Possession of this drug without authority is illegal

CARNIDAZOLE
: Available only for the treatment of pigeons

CEPHADROXIL
: Available only for the treatment of animals

CHLORAMPHENICOL
: All topical chloramphenicol preparations (sprays, powders, creams, ointments and pessaries) are withdrawn from veterinary use and oral and parenteral preparations confined to animals not used in meat, egg or milk production

2-(4-CHLOROPHENYL)-1,2,4-TRIAZOLE [5,1a]-ISOQUINOLINE
: Available only for the treatment of animals

CLANOBUTIN
: Available only for the treatment of animals

CLENBUTEROL
: Available only for the treatment of animals

CLOPROSTENOL
: Available only for the treatment of animals

DETOMIDINE
: Available only for the treatment of animals

DEXTROPROPOXYPHENE
: This drug is accountable in hospitals and possession without authority is illegal

FENPROSTALENE
: Available only for the treatment of animals

FLUNIXIN MEGLUMINE
: Available only for the treatment of animals

FLUPROSTENOL
: Available only for the treatment of animals

GLUTETHIMIDE
: Possession of this drug without authority is illegal

METERGOLINE
: Available only for the treatment of animals

NALBUPHINE

PHENTERMINE
: Supply of this drug is subject to monitoring Possession of this drug without authority is illegal

PROSTIANOL
Available only for the treatment of animals
ROMIFIDINE
Available only for the treatment of animals
SILVER SULPHADIAZINE
This substance is available only to hospitals and Royal Flying Doctor Services for the treatment of major burns and for the treatment of patients where full-thickness skin loss has occurred
SODIUM PENTOSAN POLYSULPHATE
Available only for the treatment of animals
SULPHATROXAZOLE
Available only for the treatment of animals
TILETAMINE
Available only for the treatment of animals
ZOLAZEPAM
Available only for the treatment of animals

SCHEDULE 5

POISONS OF A HAZARDOUS NATURE THAT MUST BE READILY AVAILABLE TO THE PUBLIC BUT REQUIRE CAUTION IN HANDLING, STORAGE AND USE.

ACETIC ACID – (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid CH3COOH) **except**:
(a) when included in Schedule 2 or 6; or
(b) for therapeutic use.
ACETONE **except** in preparations containing 25 per cent or less of designated solvents
AKLOMIDE
ALKALINE SALTS, being the carbonate, orthosilicate, metasilicate or tribasic phosphate salts of sodium or potassium, and in any combination, **except**:
(a) in preparations containing 10 per cent or less of combined substances;
(b) in solid preparations whose pH in 10g/L aqueous solution is 11.5 or less; or
(c) in liquid preparations having a pH of 11.5 or less.
ALLOXYDIM
AMETRYN
AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules
AMITROLE
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:
(a) in preparations for human internal therapeutic use;
(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate

ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins **except** when separately specified in these Schedules

ARSENIC organic compounds in herbicides or defoliant preparations containing 3 per cent or less of arsenic **except** when separately specified in this Schedule

AZAMETHIPHOS

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg per sq. cm.

BENALAXYL

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb

BENTAZONE

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2, 3 or 4; or

(b) in preparations containing 2 per cent or less of benzoyl peroxide.

BHC (excluding lindane) in preparations containing 10 per cent or less of BHC

BIOALLETHRIN including sinbioallethrin **except** in preparations containing 10 per cent or less of bioallethrin

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin

BORIC ACID (excluding its salts) and BORAX **except**:

(a) when included in Schedule 4;

(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or

(c) in hand cleaning preparations.

BUTHIDAZOLE

BUTOXYCARBOXIM, in solid preparations containing 10 per cent or less of butoxycarboxim

CADMIUM SULPHIDE in preparations containing 2.5 per cent or less of cadmium sulphide for human therapeutic use

CALCIUM HYPOCHLORITE **except** in preparations containing 4 per cent or less of available chlorine

CAMPHOR **except**:

(a) when included in Schedule 4;

(b) when enclosed in an inhaler device which prevents ingestion of its contents; or

(c) in preparations containing 10 per cent or less of camphor.

CARBARYL

(a) in preparations containing 10 per cent or less of carbaryl except when included in Schedule 2 or 4; or

(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CHLORFENAC

CHLORFENSON

CHLORINATED LIME **except** in preparations containing 4 per cent or less of available chlorine

CHLORINATING COMPOUNDS **except**:

(a) solid preparations containing 4 per cent or less of available chlorine;

(b) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements "WARNING: Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products", written in letters not less than 2 mm in height; or

(c) liquid preparations containing less than 2 per cent of available chlorine.

CHLORNIDINE

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol

CHLORPYRIFOS in preparations containing 5 per cent or less of chlorpyrifos

CHLORSULFURON

CLANOBUTIN for the treatment of animals **except** when included in Schedule 4

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole

CLOFENTEZINE

CLOPYRALID

COPPER SULPHATE **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5 per cent or less of copper sulphate.

4-CPA

CUPRIMYXIN for the treatment of animals

CYANATRYN

CYANOACRYLIC ESTERS in contact adhesives **except** when labelled "KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water".

CYANURIC ACID (excluding its salts and derivatives)

CYCLOHEXANONE PEROXIDE

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin

CYFLUTHRIN

(a) in wettable powders containing 10 per cent or less of cyfluthrin;

(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or

(c) in emulsions containing 5 per cent or less of cyfluthrin.

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole

2,4-D
DAMINOZIDE
2,4-DB
DDT in preparations containing 10 per cent or less of DDT, **except** dicophane when included in Schedule 2
2,4-DES
DELTAMETHRIN in aqueous formulations containing 1 per cent or less of deltamethrin, when no organic solvent, other than a glycol, is present
N, N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide
DIAZINON in dust preparations containing 2 per cent or less of diazinon
DICAMBA
DICHLOFLUANID
DICHLONE
DICHLOROISOCYANURATES **except** in preparations containing 4 per cent or less of available chlorine
DICHLOROPHEN for the treatment of animals
2',4'-DICHLORO-2-(3-PYRIDYL)-ACETOPHENONE-0-METHYLOXIME (PYRIFENOX)
DICHLORVOS
(a) when impregnated in plastic resin strip material containing 20 per cent or less dichlorvos;
(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
(c) in pressurised spray packs containing 10 grams or less of dichlorvos.
DICLOBUTRAZOL
DICLORAN
DICOFOL
DIETHYLTOLUAMIDE **except** in preparations containing 20 per cent or less of diethyltoluamide when labelled "WARNING – this product contains diethyltoluamide, which may be dangerous when used in large amounts or for a long period"
DIMETHIRIMOL
DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide
DINICONAZOLE
DIPHENAMID
DODINE
DSMA in herbicides or defoliant preparations containing 3 per cent or less of arsenic
ENILCONAZOLE
EPOXY RESINS, LIQUID
EPTC
ETHEPHON (excluding its salts and derivatives)
ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines
ETHOFUMESATE

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin

ETHYLENE GLYCOL when packed and labelled as a boiling point or freezing point modifier containing not less than 10 mg/kg of denatonium benzoate as a bittering agent

ETRIDIAZOLE

FENARIMOL

FENOPROP

FENOXAPROP-ETHYL

FENSON

FENTHION in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 ml or less

FLAMPROP-METHYL

FLUCHLORALIN

FLUMETHRIN in oil based preparations containing 1 per cent or less of flumethrin

FLUORIDES (including silicofluorides) in preparations containing 0.5 per cent or less of fluoride ion **except**:

(a) in dentifrices containing 1000 mg/kg or less of fluoride ion; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate

FURALAXYL

GLUFOSINATE – AMMONIUM

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde, **except** when included in Schedule 2

GLYPHOSATE

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole

HEXAZINONE

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths

HYDROCARBONS, LIQUID, including kerosene, mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives) distilling under 300 degrees celcius, **except**:

(a) toluene and xylene when included in Schedule 6;

(b) in solid or semi-solid preparations;

(c) in preparations containing 25 per cent or less of designated solvents;

(d) in preparations packed in pressurised spray packs; or

(e) in adhesives packed in containers each containing 50 grams or less of adhesive.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HC1) **except**:

(a) in preparations containing 0.5 per cent or less of hydrochloric acid (HC1); or

(b) for therapeutic use.

HYDROFLUORIC ACID (including hydrosilicofluoric acid but excluding their salts and derivatives) in preparations containing the equivalent of 0.5 per cent or less of hydrogen fluoride

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except** in preparations containing 6 per cent (20 vol) or less of hydrogen peroxide

IMAZALIL

IMAZETHAPYR

IODOCARB **except** in aqueous preparations containing 10 per cent or less of iodocarb

ISOPHORONE

LEAD COMPOUNDS in preparations for use as hair cosmetics

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals, **except** when included in Schedule 4

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4

MALDISON in preparations containing 10 per cent or less of maldison **except**:

(a) when included in Schedule 2 or 4; or

(b) in dust preparations containing 2 per cent or less of maldison.

MANCOZEB

MCPA

MCPB

MECOPROP

MEPIQUAT

METALAXYL

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde

METHABENZTHIAZURON

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb

METHOXYCHLOR

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) excluding its preparations and admixtures **except** in containers having a capacity of more than 5 litres

METHYLENE CHLORIDE **except** in pressurised spray packs other than when packed and labelled as degreasers, decarbonisers or paint strippers that contain more than 10 per cent of methylene chloride

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents

METHYL ETHYL KETONE PEROXIDE

METHYL ISO-AMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents
METHYL ISO-BUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents
METHYL SALICYLATE in liquid preparations containing 25 per cent or more of methyl salicylate **except** when included in Schedule 6
N-(3-METHYL-4-THIAZOLIN-2-YLIDENE)-2,4-XYLIDINE (Cymiazole)
METIRAM
METOLACHLOR
METRIBUZIN
MEZINEB
MSMA in herbicides or defoliant preparations containing 3 per cent or less of arsenic
MYCLOBUTANIL
NAA **except** in preparations containing 25 per cent or less of NAA
NALED when impregnated in plastic resin strip material contaiing 20 per cent or less of naled
NAPHTHALENE as such
NAPTALAM
NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) **except** preparations containing 0.5 per cent or less of nitric acid
NORBORMIDE
OFURACE
OXADIXYL
OXYCARBOXIN
OXYTHIOQUINOX
PACLOBUTRAZOL
PARADICHLOROBENZENE
PEBULATE
PENCONAZOLE
PENDIMETHALIN
PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid
PETROL **except** preparations containing 25 per cent or less of petrol
PHENISOPHAM
PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents
Ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or les of o-phenylphenol
PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H3PO3)
PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when packed in containers having a capacity of not less than 10 litres and labelled with the word "CORROSIVE" in bold face sanserif capital letters of a height of not less than 1 cm;
(b) in preparations containing 350 g/litre or less of phosphoric acid (H3PO4);

(c) in solid and semi-solid preparations; or
(d) in professional dental kits.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb

POLYETHANOXY (15) TALLOW AMINE

POLY (HEXAMETHYLENE BIGUANIDE) **except** in preparations containing 5 per cent or less of poly (hexamethylene biguanide)

POTASSIUM CHLORATE **except**:
(a) when included in Schedule 2; or
(b) in preparations containing 10 per cent or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide, **except** in preparations containing 0.5 per cent or less of potassium hydroxide

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite

POTASSIUM SULPHIDE in preparations for metal treatment in containers each containing 50g or less of potassium sulphide

PROMETRYN

PROPAMOCARB

PROPANIL

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:
(a) in preparations containing 30 per cent or less of propionic acid; or
(b) for therapeutic use.

PROPOXUR
(a) in dust preparations containing 3 per cent or less of propoxur;
(b) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
(c) in aerosol packs containing 10 g or less of propoxur; or
(d) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except** in preparations containing 10 per cent or less of such substances

QUATERNARY AMMONIUM COMPOUNDS **except**:
(a) when separately specified in these Schedules; or
(b) in preparations containing 10 per cent or less of quaternary ammonium compounds.

QUINTOZENE

SALICYLANILIDE

SELENIUM SULPHIDE in preparations for topical therapeutic use containing 2.5 per cent or less of selenium sulphide

SETHOXYDIM

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate
SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate
SODIUM HYDROGEN SULPHATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulphate
SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide **except** in liquid preparations having a pH of 11.5 or less
SODIUM HYPOCHLORITE **except** in preparations containing 4 per cent or less of available chlorine
SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite
SODIUM NITRITE **except**:
(a) when included in Schedule 2; or
(b) in preparations containing 1 per cent or less of sodium nitrite.
SODIUM SULPHIDE
(a) in preparations for metal treatment in containers each containing 50 g or less of sodium sulphide; or
(b) in preparations for use as insect lures.
STYRENE (excluding its derivatives)
SULFOMETURON-METHYL
SULPHAMIC ACID **except** in preparations containing 10 per cent or less of sulphamic acid (H3NO3S)
2,3,6-TBA
TDE (1,1-dichloro-2,2-bis (4-chlorophenyl) ethane) in preparations containing 10 per cent or less of TDE
TEBUCONAZOLE
TEMEPHOS
(a) in liquid preparations containing 10 per cent or less of temephos;
(b) in powders containing 2 per cent or less of temephos; or
(c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 ml or less.
TERBUTRYN
TETRACHLOROETHYLENE in preparations containing 5 per cent or less tetrachloroethylene **except**:
(a) when prepared for therapeutic use; or
(b) when absorbed into an inert solid.
TETRACHLORVINPHOS **except** in animal feed containing 0.2 per cent or less of tetrachlorvinphos
TETRAMETHRIN (R,cis): (R, trans) = 20:80 **except** in pressurised spray packs
THIFENSULFURON
THIOBENCARB
TIOCARBAZIL
TOLCLOFOS-METHYL
TRALKOXYDIM

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon
TRIADIMENOL
TRI-ALLATE
TRICHLOROACETIC ACID, alkali salts of
1,1,1-TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs other than for therapeutic use;
(b) in preparations containing 25 per cent or less of designated solvents;
(c) in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 ml or less; or
(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 ml or less labelled with:
    (i) the word "Trichloroethane" written in letters not less than 1 mm in height and in distinct contrast to the background; and
    (ii) the expression "WARNING: DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU", written in bold face sanserif capital letters not less than 1mm in height and in distinct contrast to the background.

TRICHLOROISOCYANURIC ACID in compressed block form for use in swimming pools or toilet cisterns
TRIDIPHANE
TRIETAZINE
TRIFLUMIZOLE
TRIFLUMURON
TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil
VERNOLATE
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin
ZIRAM

SCHEDULE 6

POISONS THAT MUST BE AVAILABLE TO THE PUBLIC BUT ARE OF A MORE HAZARDOUS OR POISONOUS NATURE THAN THOSE CLASSIFIED IN SCHEDULE 5.

ACEPHATE
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent acetic acid (CH3COOH) **except** when included in Schedule 2
ACETIC ANHYDRIDE excluding its derivatives
ACIFLUORFEN
ALBENDAZOLE in preparations for the treatment of animals
ALDRIN

AMIDITHION
AMINOCARB in preparations containing 25 per cent or less of aminocarb
AMITRAZ
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:
(a) when included in Schedule 5;
(b) in preparations for human internal therapeutic use; or
(c) in preparations for inhalation when absorbed in an inert solid material; or
(d) in preparations containing 0.5 per cent or less of ammonia.
ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or les of aniline
ANTIMONY COMPOUNDS **except**:
(a) when included in Schedule 4;
(b) antimony chloride in polishes; or
(c) antimony titanate pigments in paint.
ARECOLINE
ARSENIC (**except** where separately specified in this schedule):
(a) in ant poisons containing 0.4 per cent or less of arsenic;
(b) organic compounds of arsenic in herbicides or defoliant preparations **except** when included in Schedule 5;
(c) in animal feed premixes containing 4 per cent or less of arsenic;
(d) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4; or
(e) in paints containing more than 0.1 per cent of arsenic when calculated on the basis of the non-volatile content of the paint.
ASPIRIN for the treatment of animals **except** when included in Schedule 4
AVERMECTIN B1 in preparations containing 1 per cent or less of avermectin B1, for the treatment of animals, when supplied in sealed containers for use in automatic injection equipment
AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole
AZOBENZENE
BACITRACIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances
BARIUM SALTS **except**:
(a) when included in Schedule 5; or
(b) barium sulphate; or
(c) barium metaborate in paint.
BENDIOCARB
(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100g of bendiocarb;
(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48g of bendiocarb and labelled for use as a fly control preparation; or

(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb;

except when included in Schedule 5.

BENOMYL

BENQUINOX

BENSULIDE

5-BENZYLFUR-3-YLMETHYL (1'R,3'S.E)-2',2'-DIMETHYL-3'-(2-OXO-2,3,4,5-TETRAHYDRO-3-THIENYLIDENEMETHYL) -CYCLOPROPANE CARBOXYLATE

BENZYLPENICILLIN in preparations, for intramammary infusion in animals, containing not more than 100 000 International Units of benzylpencillin per dose

BERYLLIUM

BHC (excluding lindane) **except** when included in Schedule 5

BITHIONOL for treatment of animals

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin

BROMOFORM **except** when included in Schedule 4

BROMOPHOS

BROMOPHOS-ETHYL

BROMOXYNIL

BROTIANIDE

BUNAMIDINE

BUTACARB

BUTOXYCARBOXIM **except** when included in Schedule 5

2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER

BUTYNORATE

CACODYLIC ACID in animal feed premixes containing 4 per cent or less of arsenic

CADMIUM COMPOUNDS **except** when included in Schedule 5

CAJUPUT OIL **except** in oils or preparations containing 25 per cent or less of cineole

CALCIFEROL in rodent baits containing 1 g/kg or less of calciferol

CAMBENDAZOLE

CARBARYL **except** when included in Schedule 2,4 or 5

CARBENDAZIM

CARBON DISULPHIDE

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide

CHLORDANE

CHLORFENETHOL

CHLORMEQUAT

N-[5-CHLORO-4-[(4-CHLOROPHENYL)-CYANOMETHYL]-2-METHYLPHENYL]-2-HYDROXY-3,5-DIIODOBENZAMIDE

CHLOROFORM **except**:
(a) when included in Schedule 2 or 4; or
(b) in preparations containing 10 per cent or less of chloroform.
alpha-CHLOROHYDRIN
CHLOROPHACINONE
CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin
CHLOROTHALONIL
CHLORPYRIFOS **except** when included in Schedule 5
CHLORPYRIFOS-METHYL
CHLORTETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of chlortetracycline per dose.
CHLORTHIAMID
CHOLECALCIFEROL in rodent baits containing 1 g/kg or less of cholecalciferol
CHROMATES (including dichromates) **except** chromates of barium, potassium, sodium, strontium, zinc or ammonia in paint containing 5 per cent or less of chromium, calculated on the nonvolatile content of the paint
CHROMIUM TRIOXIDE (excluding its salts and derivatives)
CINEOLE **except** in oils or preparations containing 25 per cent or less of cineole
CLIMBAZOLE **except**:
(a) when included in Schedule 5; or
(b) in preparations containing 2 per cent or less of climbazole.
CLOTRIMAZOLE for external treatment of animals
COUMAPHOS in preparations containing 5 per cent or less of coumaphos
COUMATETRALYL
CREOSOTE **except**:
(a) when included in Schedule 2; or
(b) in preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220 degrees celcius.
CROTOXYPHOX
CRUFOMATE
CYANAMIDE
CYANAZINE
CYFLUTHRIN **except**:
(a) when included in Schedule 5; or
(b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.
CYOMETRINIL
CYPERMETHRIN **except** when included in Schedule 5
CYTHIOATE
DAZOMET
DDT and its preparations **except**:
(a) when included in Schedule 5; or

(b) dicophane included in Schedule 2.

DEMETON-O-METHYL in preparations containing 10 per cent or less of demeton-o-methyl or demeton-o-methyl and demeton-s-methyl

DEMETON-S-METHYL in preparations containing 10 pere cent or less of demeton-s-methyl or demeton-s-methyl and demeton-o-methyl

DIAZINON **except** when included in Schedule 5

TRANS-4-(3,5-DIBROMO-2-HYDROXYBENZYL)-AMINO CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE (Sputolysin) in oral preparations for the treatment of animals

DICHLOFENTHION

ortho-DICHLOROBENZENE

DICHLOROETHYL ETHER,

DICHLOROPHEN **except** when included in Schedule 5

1,2-DICHLOROPROPANE

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5

DICLOFOP-METHYL

DIELDRIN

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum

DIFENZOQUAT

DIHYDROSTREPTOMYCIN in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of dihydrostreptomycin per dose

DIMETHIPIN

DIMETHOATE

1,3-DI (METHOXYCARBONYL)-1-PROPEN-2-YL-DIMETHYL PHOSPHATE in preparations containing 25 per cent or less of 1,3-di (methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate

DIMETHYLFORMAMIDE **except** when included in Schedule 5

DIMETHYL SULPHOXIDE

(a) when not for therapeutic use; or

(b) for the treatment of animals;

(i) when combined with no other therapeutic substance; or

(ii) in preparations containing copper salicylate as the only other therapeutic substance.

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINOCAP

DIOXACARB

DIOXANE

DIPHACINONE

DIQUAT

DISULFIRAM **except** when included in Schedule 4
DISULFOTON in granular preparations containing 5 per cent or less of disulfoton
DITHIANON
DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals
DIUREDOSAN
DSMA in herbicides or defoliant preparations **except** when included in Schedule 5
ECONAZOLE for external treatment of animals
ENDOSULFAN
ENDOTHAL in preparations containing 20 per cent or less of endothal
ERYTHROMCYIN
(a) in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of erythromycin per dose; or
(b) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
ESFENVALERATE
ETHER **except**:
(a) when included in Schedule 2,4 or 5; or
(b) in preparations containing 10 per cent or less of ether.
ETHIOFENCARB
ETHOATE-METHYL
ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil
ETHYL BROMIDE
ETHYLENE CHLOROHYDRIN
ETHYLENE DICHLORIDE
ETHYLENE GLYCOL when packed and labelled as a boiling point or freezing point modifier **except** when included in Schedule 5
ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except** in preparations containing 10 per cent or less of such substances
ETRIMFOS
EUCALYPTUS OIL **except** in preparations containing 25 per cent or less of eucalyptus oil
FAMPHUR in preparations containing 20 per cent or less of famphur
FENAMINOSULF in preparations containing 10 per cent or less of fenaminosulf when labelled and packed as dry seed dressings
FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos
FENAZAFLOR
FENBUTATIN OXIDE
FENCHLORPHOS
FENITROTHION
FENOXACARIM in preparations for the treatment of carpets during manufacture
FENTHION **except** when included in Schedule 5

FENVALERATE
FLAVOPHOSPHOLIPOL in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances
FLOCOUMAFEN in preparations containing 0005 per cent or less of flocoumafen
FLUAZIFOP-BUTYL
FLUAZIFOP-P-BUTYL
FLUCOFURON in preparations for the treatment of carpets during manufacture
FLUMETHRIN **except** when included in Schedule 5
FLUORIDES (including silicofluorides), **except**:
(a) when included in Schedule 2, 3, 4 or 5;
(b) in preparations containing 3 per cent or less of sodium fluoride or sodium silicofluoride as preservatives;
(c) in pesticide preparations containing 3.2 per cent or less of ammonium silicofluoride;
(d) in dentifrices containing 1000 mg/kg or less of fluoride ion; or
(e) in preparations containing 15 mg/kg or less of fluoride ion.
FLUSILAZOL
FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol
FLUVALINATE **except** when included in Schedule 5
FORMALDEHYDE (excluding its derivatives other than paraformaldehyde) **except** in preparations containing 5 per cent or less of formaldehyde
FORMOTHION
FOSPIRATE **except** when included in Schedule 5
FUMAGILLIN
GLUTARALDEHYDE **except** when included in Schedule 2 or 5
GLYCERYL THIOGLYCOLLATE in hair waving preparations unless the directions for use include "Wear protective gloves when using. Keep out of eyes"
GUAZATINE
HALOXON
HALOXYFOP
HEPTACHLOR
HEXACHLOROPHANE in preparations for the treatment of animals
HYDRAMETHYLNON **except** when included in Schedule 5
HYDRAZINE
HYDROCHLORIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of hydrochloric acid (HC1)
HYDROFLUORIC ACID (including hydrosilicofluoric acid but excluding their salts and derivatives) in preparations containing the equivalent of 10 per cent or less of hydrogen fluoride **except** when included in Schedule 5
HYDROQUINONE **except**:
(a) when included in Schedule 2 or 4; or
(b) in preparations containing 10 per cent or less of hydroquinone.
HYGROMYCIN for use as an anthelmintic, in animal feed premixes containing 2 per cent or less of antibiotic substances

IMIDOCARB
IODINE (excluding its salts, derivatives and iodophors) **except**:
(a) when included in Schedule 2; or
(b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.
IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine
IOXYNIL
IRON COMPOUNDS for the treatment of animals **except**:
(a) in liquid or gel preparations containing 0.1 per cent or less of iron; or
(b) in animal feeds and feed premixes.
ISOCONAZOLE for external treatment of animals
ISOCYANATES free organic
IVERMECTIN
(a) in preparations containing 0.8g/L of ivermectin for the treatment of sheep;
(b) in pre-loaded syringes containing 10g or less of a paste containing 2 per cent or less of ivermectin for the treatment of horses; or
(c) in preparations containing 1 per cent or less of ivermectin, for the treatment of bovine cattle, when supplied in sealed containers for use in automatic injection equipment.
KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances
LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances
LAURYLISOQUINOLINIUM BROMIDE
LEAD COMPOUNDS **except**:
(a) when included in Schedule 4 or 5;
(b) in preparations for cosmetic use containing 100 mg/kg or less of lead; or
(c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead.
LEVAMISOLE for the treatment of animals **except**:
(a) when included in Schedule 4 or 5; or
(b) in preparations for the treatment of ornamental birds or ornamental fish in packs containing 10 mg or less of levamisole.
LINDANE **except** when included in Schedule 2, 4 or 5
MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances
MAFENIDE for the treatment of aquarium fish
MALDISON **except**:
(a) when included in Schedule 2, 4 or 5; or
(b) in dust preparations containing 2 per cent or less of maldison.
MEBENDAZOLE for the treatment of animals
MECLOFENAMIC ACID for the treatment of animals

MEFLUIDIDE
MELALEUCA OIL (TEA-TREE OIL) **except** in preparations containing 25 per cent or less of melaleuca oil
MENAZON
MERCURIC OXIDE for the treatment of animals, in preparations for ocular use
MERCUROCHROME for the treatment of animals, in preparations for topical use
METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals
METALDEHYDE **except** when included in Schedule 5
METHAM
METHANOL (excluding its derivatives) **except**:
(a) when included in Schedule 5; or
(b) in preparations containing 2 per cent or less of methanol.
METHAZOLE
METHIOCARB **except** when included in Schedule 5
METHOMYL in fly-baits containing one per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent
METHYL CHLORIDE
METHYLENE BISTHIOCYANATE **except** in preparations containing one per cent or less of methylene bisthiocyanate
METHYL ISOTHIOCYANATE
METHYL SALICYLATE excluding admixtures (see also Schedule 5)
MICONAZOLE for the external treatment of animals
MOLINATE
MONENSIN
(a) in animal feed premixes for growth promotion or for coccidiosis prevention containing 12.5 per cent or less of monensin; or
(b) in intraruminal implants for cattle each containing 35 g or less of monensin.
MSMA in herbicides or defoliant preparations **except** when included in Schedule 5
NALED **except** when included in Schedule 5
NALIDIXIC ACID when packed and labelled for the treatment of ornamental fish
NAPHTHALOPHOS when specifically prepared and packed for use as a sheep drench
NARASIN in animal feed premixes containing 120 g/kg or less of narasin
NEOMYCIN in preparations for topical application to animals for ocular use only
NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals
NIMIDANE in preparations containing 25 per cent or less of nimidane
NITHIAMIDE **except** in preparations containing 20 per cent or less of nithiamide
NITRIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of nitric acid (HNO3)

NITROBENZENE **except**:
(a) in solid or semi-solid polishes;
(b) in soaps containing 1 per cent or less of nitrobenzene; or
(c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROPHENOLS, ortho, meta and para

NITROSCANATE

NITROXYNIL

NOVOBIOCIN in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of novobiocin per dose

2-OCTYL-4-ISOTHIAZOLIN-3-ONE (Octhilinone)

OESTRADIOL
(a) in ear implants for growth promotion in bovine cattle; or
(b) in combination with progesterone, testosterone or trenbolone in ear implants for growth promotion in bovine cattle.

OLAQUINDOX in animal feed premixes for growth promotion

OLEANDOMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances

OMETHOATE in preparations containing 50 per cent or less of omethoate

OXADIAZON

OXALIC ACID **except** its derivatives and insoluble salts

OXANTEL EMBONATE for the treatment of animals

OXFENDAZOLE

OXYCLOZANIDE

OXYTETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) for intramammary infusion in animals, containing not more than 100 000 International Units of oxytetracyclione per dose.

PARBENDAZOLE

PENTACHLOROPHENOL **except** in preparations containing 1.5 per cent or less of pentachlorophenol

PERACETIC ACID **except** when included in Schedule 5

PERFLUIDONE

PERMANGANATES

PHENETHICILLIN in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of phenethicillin per dose

PHENOL, or any homologue of phenol boiling below 220 degrees celcius, **except**:
(a) when included in Schedule 2; or
(b) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine

PHENOXYMETHYLPENICILLIN in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of phenoxymethylpenicillin per dose

PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in this Schedule or in Schedule 2:
- (a) when used in hair dyes;
- (b) in preparations packed and labelled for photographic purposes; or
- (c) in preparations packed and labelled for testing water **except** in tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, "Do not discard testing solutions into the pool".

PHOSALONE
PHOSMET
PHOSPHIDES, METALLIC
PHOXIM
PICRIC ACID (excluding its derivatives) **except** in preparations containing 5 per cent or less of picric acid
PINDONE
PIPEROPHOS
PIRIMICARB **except** when included in Schedule 5
PIRIMIPHOS-ETHYL
PIRIMIPHOS-METHYL
POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate
POTASSIUM CYANATE
POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:
- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5 per cent or less of potassium hydroxide.

PROCAINE PENICILLIN in preparations, for intramammary infusion in animals, containing not more than 100 000 International Units of procaine penicillin per dose
PROCHLORAZ
PROFENOFOS
PROGESTERONE
- (a) in a silicone rubber elastomer when used as a controlled-released implant for synchronisation of oestrus in cattle; or
- (b) in combination with oestradiol or trenbolone in ear implants for growth promotion in bovine cattle.

PROMACYL
PROMECARB in preparations containing 50 per cent or less of promecarb
PROPACHLOR
PROPARGITE
PROPETAMPHOS
PROPICONAZOLE **except** when included in Schedule 5
PROPINEB
PROPIONIC ACID (excluding its salts and derivatives) **except**:
- (a) when included in Schedule 5;
- (b) in preparations containing 30 per cent or less of propionic acid; or
- (c) for therapeutic use.

PROPOXUR **except** when included in Schedule 4 or 5
PROTHIOFOS
PYRAZOPHOS
QUIZALOFOP ETHYL
QUIZALOFOP ETHYL (D+ ISOMER)
SALINOMYCIN in animal feed premixes containing 6 per cent or less of antibiotic substances
SELENIUM
- (a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
  - (i) for the blueing of gun barrels; or
  - (ii) for photographic purposes;
- (b) in coated fertiliser granules containing 1 per cent or less of selenium except in fertilisers containing 200 g/tonne or less of selenium;
- (c) in a drench, injection, paste, stocklick or vaccine containing 0.5 per cent or less of selenium for the treatment of animals; or
- (d) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 0.1 g/tonne or less of selenium.

SILVER NITRATE **except**:
- (a) when included in Schedule 2; or
- (b) in chewing tablets.

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate
SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:
- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5 per cent or less of sodium hydroxide.

SPIRAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances
STREPTOMYCIN in preparations for intramammary infusion in animals, containing not more than 100 000 International Units of streptomycin per dose
SULCOFURON in preparations for the treatment of carpets during manufacture
SULPHONAMIDES when packed and labelled for treatment of ornamental caged birds or ornamental fish only
SULPHAQUINOXALINE when packed and labelled for use as a coccidiostat in poultry **except** preparations containing 200 mg/kg or less of sulphaquinoxaline
SULPHURIC ACID (excluding its salts and derivatives) **except**:
- (a) in fire extinguishers; or
- (b) in preparations containing 0.5 per cent or less of sulphuric acid (H_2SO_4).

SULPROPHOS
2,4,5-T
TCMTB (2-[thiocyanomethylthio]benzothiazole)

TDE (1,1-dichloro-2,2-bis (4-chlorophenyl) ethane) **except** when included in Schedule 5

TEMEPHOS **except** when in Schedule 5

TERBUTHYLAZINE

TERPENES, CHLORINATED

TESTOSTERONE

(a) testosterone cyprionate, dipropionate, enanthate and propionate in preparations labelled for treatment and prevention of pizzle (sheath) rot in wethers;

(b) in preparations labelled for masculinisation of wethers for use as 'teaser rams' to stimulate and detect reproductive activity in ewes;

(c) in combination with oestradiol or trenbolone in ear implants for growth promotion in bovine cattle; or

(d) in oil preparations for growth promotion purposes labelled for injection at the base of the ear in sheep.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 5;

(b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or

(c) for therapeutic use.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only;

(b) for intramammary infusion in animals, containing not more than 100 000 International Units of tetracycline per dose; or

(c) when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

TETRADIFON

2,2'-6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide

2,2,3,3-TETRAFLUOROPROPIONIC ACID (FLUPROPANATE)

TETRAMISOLE in preparations for the treatment of animals

THIAZAFLURON

THIODICARB

THIOMETON

THIOUREA AND ALKYL THIOUREAS **except** for therapeutic use

THIRAM

TIAMULIN for the treatment of animals:

(a) in feed premixes containing 25 per cent or less of tiamulin; or

(b) in soluble concentrates containing 45 per cent or less of tiamulin.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule;

(b) in plastics; or

(c) in paint containing 1 per cent or less of tin.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene

TRENBOLONE
- (a) in ear implants for growth promotion in bovine cattle; or
- (b) in combination with oestradiol, progesterone or testosterone in ear implants for growth promotion in bovine cattle.

TRIADIMEFON **except**:
- (a) when included in Schedule 5; or
- (b) in fertilisers containing 5g/kg or less of triadimefon.

TRICHLORFON
TRICHLOROACETIC ACID **except** when included in Schedule 5
TRICHLOROETHYLENE **except** when included in Schedule 4
TRICHLOROPHENOL
TRICLOPYR
TRIDEMORPH
TRIETHYL PHOSPHATE
TRIFLUOROMETHANE SULPHONIC ACID
TYLOSIN in animal feed premixes for growth promotion containing 5 per cent or less of antibiotic substances
VAMIDOTHION
VIRGINIAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances
WARFARIN **except**:
- (a) when included in Schedule 4 or 5; or
- (b) for external therapeutic use.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene
ZERANOL in ear implants for use as a growth promotant in steer cattle
ZINC CHLORIDE **except** in preparations containing 5 per cent or less of zinc chloride
ZINC p-PHENOLSULPHONATE **except** in preparations containing 5 per cent or less of zinc p-phenolsulphonate
ZINC SULPHATE **except**:
- (a) when included in Schedule 4;
- (b) in preparations for human internal use with a recommended daily dose of 50 mg or less of zinc; or
- (c) in other preparations containing 5 per cent or less of zinc sulphate.

SCHEDULE 7

POISONS WHICH REQUIRE SPECIAL PRECAUTIONS IN MANUFACTURE, HANDLING, STORAGE OR USE, OR SPECIAL INDIVIDUAL REGULATIONS REGARDING LABELLING OR AVAILABILITY.

ACROLEIN
Available only to authorised or licensed persons for approved research purposes or for industrial and manufacturing purposes

ACRYLONITRILE
Available only for research purposes or for industrial and manufacturing purposes

ALACHLOR
Available only for research purposes

ALDICARB
Available in granular form only and not in packs for domestic use

ALDOXYCARB
Not to be made available in packs for domestic use

ALLYL ALCOHOL
Available only to authorised or licensed persons for approved research purposes or for industrial and manufacturing purposes

AMINOCARB **except** when included in Schedule 6
Not to be made available in packs for domestic use

4-AMINOPYRIDINE **except** when included in Schedule 4
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

AMITON
Not to be made available in packs for domestic use

ARPRINOCID
Available only for approved toxicological research purposes

ARSENIC **except**:
(a) thiacetarsamide when included in Schedule 4;
(b) when included in Schedule 5 or 6;
(c) selenium arsenide in photocopier drums; or
(d) in animal feeds containing 75g/tonne or less of arsenic.
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

AVERMECTIN B1 **except** when included in Schedule 6
Available only to authorised or licensed persons, in sealed containers, for use in automatic injection equipment

AZINPHOS-ETHYL
Not to be made available in packs for domestic use

AZINPHOS-METHYL
Not to be made available in packs for domestic use

AZOCYCLOTIN
Available only to authorised or licensed persons

BENDIOCARB **except** when included in Schedule 5 or 6
Not to be made available in packs for domestic use

BENZENE (excluding its derivatives) **except**:
(a) preparations containing 15ml/L or less of benzene; or
(b) petrol containing 50ml/L or less of benzene.
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

BRODIFACOUM **except** when included in Schedule 6
Available for industrial and manufacturing purposes only

BROMADIOLONE **except** when included in Schedule 6
Available for industrial and manufacturing purposes only

BROMETHALIN **except** when included in Schedule 6

BROMINE (excluding its salts and derivatives)
Available only for research purposes or industrial and manufacturing purposes

BRUCINE **except** when used in concentrations of 0.02 per cent or less for the denaturation of alcohol
Available only for research purposes or industrial and manufacturing purposes

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6
Available only to authorised or licensed persons for industrial and manufacturing purposes

CAPTAFOL
Available only for research purposes, industrial and manufacturing purposes, essential uses where operator exposure is minimal. Not available in pakcs for domestic use

CAPTAN
Available only for research purposes, industrial and manufacturing purposes, essential uses where operator exposure is minimal. Not available in packs for domestic use

CARBADOX
Available only for approved research purposes

CARBOFURAN
Not to be made available in packs for domestic use

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing less than 1 per cent of carbon tectrachloride.
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

CARBOPHENOTHION
Not to be made available in packs for domestic use

CHLORDECONE
Available only for research purposes

CHLORDIMEFORM
Available for approved research purposes only and not in packs for domestic use. Not to be used in agricultural or veterinary chemical formulations or printing inks or ink additives.

CHLORFENVINPHOS
Not to be made available in packs for domestic use

CHLORINE (excluding its salts and derivatives)
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

CHLOROMETHIURON
Available only for approved research purposes

5-CHLORO-3-METHYL-4-NITROPYRAZOLE
Available to commercial citrus growers only and not in packs for domestic use

4-CHLORO-o-TOLUIDINE
Available only for approved research purposes

CHLOROPICRIN **except** when included in Schedule 6
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes
CHLORTHIOPHOS
Not to be made available in packs for domestic use
CHOLECALCIFEROL for use as a rodenticide **except** when included in Schedule 6
Available only to authorised or licensed persons for industrial and manufacturing purposes
COUMAPHOS **except** when included in Schedule 6
Not to be made available in packs for domestic use
CYANIDES **except**:
(a) ferricyanides; or
(b) ferrocyanides.
CYHALOTHRIN (RS, 1R, cis,Z) : (RS, 1S, cis,Z) = 50:50
Not to be made available in packs for domestic use
CYHEXATIN
Available only to authorised or licensed persons
DELTAMETHRIN **except** when included in Schedule 6
Not to be made available in packs for domestic use
DEMETON
Not available for use as a pesticide
DEMETON-O-METHYL **except** when included in Schedule 6
Not to be made available in packs for domestic use
DEMETON-S-METHYL **except** when included in Schedule 6
Not to be made available in packs for domestic use
DIALIFOS
Not to be made available in packs for domestic use
4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline)
Available only to authorised or licnesed persons
1,2-DIBROMO-3-CHLOROPROPANE
Available only for approved toxicological research purposes
1,3-DICHLOROPROPENE
Available only to authorised or approved persons for research purposes
DICHLORVOS **except** when included in Schedule 5 or 6
Not to be made available in packs for domestic use
DICROTOPHOS
Not to be made available in packs for domestic use
DIENOCHLOR
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes
DIFENACOUM **except** when included in Schedule 6
Available for industrial and manufacturing purposes only
DIMEFOX
Not to be made available in packs for domestic use

1,3-DI (METHOXYCARBONYL)-1-PROPEN-2-YL-DIMETHYL PHOSPHATE
except when included in Schedule 6
Not to be made available in packs for domestic use

N,N-DIMETHYL-4-(PHENYLAZO)-BENZAMINE
Available only for research purposes

DIMETHYL SULPHATE

DIMETILAN
Not available for use as a pesticide

DINITROCRESOLS **except** when included in Schedule 4 or 6
Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

DINITROPHENOLS **except** when included in Schedule 4 or 6 Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes

DINOSEB
Available only for research purposes or industrial and manufacturing purposes

DISULFOTON **except** when included in Schedule 6
Not to be made available in packs for domestic use

ENDOTHAL **except** when included in Schedule 6

ENDRIN
Not to be made available in packs for domestic use

EPICHLOROHYDRIN
Available for industrial and manufacturing purposes only

ETACONAZOLE
Available only for approved toxicological research purposes

ETHION
Not to be made available in packs for domestic use

ETHOPROPHOS **except** when included in Schedule 6
Not to be made available in packs for domestic use

ETHYLENE DIBROMIDE
Available only to authorised or licensed persons, where operator exposure can be prevented and users are monitored for exposure

ETHYLENE OXIDE
Available only to authorised or licensed persons for approved research purposes and for approved industrial and manufacturing purposes

FAMPHUR **except** when included in Schedule 6
Not to be made available in packs for domestic use

FENAMINOSULF **except** when included in Schedule 6
Not to be made available in packs for domestic use

FENAMIPHOS **except** when included in Schedule 6
Not to be made available in packs for domestic use

FENOXACARIM **except**:
(a) when included in Schedule 6; or
(b) in treated carpets.
Available for industrial and manufacturing purposes only

FENSULFOTHION
Not to be made available in packs for domestic use

FENTHION-ETHYL
Not to be made available in packs for domestic use
FLOCOUMAFEN **except** when included in Schedule 6
Available for industrial and manufacturing purposes only
FLUCYTHRINATE
Not to be made available in packs for domestic use
FLUOROACETAMIDE
Available for use by accredited Government Vermin Control Officers only
FLUOROACETIC ACID
Available for use by accredited Government Vermin Control Officers only
FOLPET
Available only for research purposes, industrial and manufacturing purposes and essential uses where operator exposure is minimal Not available in packs for domestic use
FORMETANATE
Not to be made available in packs for domestic use
HALOFUGINONE **except** in prepared stockfeeds containing 3g/tonne or less of halofuginone
Available for industrial and manufacturing purposes only
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS **except** as a contaminant in proportions not exceeding those recommended by relevant Commonwealth, State or Territory legislation.
Available for approved research purposes only. Unauthorised possession prohibited.
HCB
Available only for approved research purposes and industrial and manufacturing purposes
HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350 degrees celcius **except** when in solid polymers. These oils are not to be used in agricultural or veterinary chemical formulations or in printing inks or ink additives.
HYDROCYANIC ACID (excluding its salts and derivatives) **except** when included in Schedule 4
Available to authorised or licensed persons only for research purposes and for approved industrial and manufacturing purposes
HYDROFLUORIC ACID (including hydrosilicofluoric acid but excluding their salts and derivatives) **except** when included in Schedule 5 and 6
Available for industrial and manufacturing purposes only
HYDROGEN SULPHIDE
ISOCARBOPHOS
Not to be made available in packs for domestic use
ISOFENPHOS
Not to be made available in packs for domestic use
IVERMECTIN **except** when included in Schedule 4 or 6
Available only for approved research purposes

LEPTOPHOS

Not to be made available in packs for domestic use

MADURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

Available only for research purposes

MAZIDOX

Not to be made available in packs for domestic use

MECARBAM

Not to be made available in packs for domestic use

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes

Not to be made available in packs for domestic use

MERCURY **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 2, 4 or 6;

(c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;

(d) mercury (metallic) in scientific instruments; or

(e) dental amalgams.

Available only for research purposes and industrial and manufacturing purposes. Not available for use as a pesticide or in packs for domestic use.

METHACRIFOS

Available only for approved research purposes

METHAMIDOPHOS

Not to be made available in packs for domestic use

METHAPYRILENE

Available only for approved research purposes

METHIDATHION

Not to be made available in packs for domestic use

METHOMYL **except** when included in Schedule 6

Not to be made available in packs for domestic use

METHYL BROMIDE

Available only to authorised or licensed persons for approved research purposes and for approved industrial and manufacturing purposes

4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA)

Available only to authorised or licensed persons

MEVINPHOS

Not to be made available in packs for domestic use

MIPAFOX

Not to be made available in packs for domestic use

MIREX

Available only to authorised or licensed persons

MONOCROTOPHOS

Not to be made available in packs for domestic use

NAPHTHALOPHOS **except** when included in Schedule 6
Not to be made available in packs for domestic use
NICOTINE **except**:
(a) when included in Schedule 3, 4 or 6; or
(b) in tobacco prepared and packed for smoking.
Available only for approved research purposes and industrial and manufacturing purposes. Not available for use as a pesticide
NIMIDANE **except** when included in Schedule 6
Not to be made available in packs for domestic use
NITROFEN
Available only for approved toxicological research purposes.
NITROFURANS for the treatment of animals. Human exposure to be avoided and usage discouraged.
OMETHOATE **except** when included in Schedule 6
Not to be made available in packs for domestic use.
OXAMYL
Not to be made available in packs for domestic use.
OXYFLUORFEN
Not to be made available in packs for domestic use.
PARAQUAT
Available only in packs of not less than 5 kg in which the contents are coloured blue or green and contain a stenching agent. Not available in packs for domestic use.
PARATHION
Not to be made available in packs for domestic use.
PARATHION-METHYL
Not to be made available in packs for domestic use.
PENTACHLOROPHENOL **except** when included in Schedule 6
PHORATE
Not to be made available in packs for domestic use.
PHOSFOLAN
Not to be made available in packs for domestic use.
PHOSPHINE
Available only to authorised or licensed persons.
PHOSPHORUS, YELLOW (excluding its salts and derivatives).
Available only for research purposes and industrial and manufacturing purposes and not as a pesticide.
POLYCHLORINATED BIPHENYLS
Available only for approved research purposes for approved industrial and manufacturing purposes only in totally enclosed systems and not in industries which handle process or store foods, animal feeds or packaging materials.
PROMECARB **except** when included in Schedule 6
Not to be made available in packs for domestic use.
PROPYLENE OXIDE
Available only to authorised or licensed persons for approved research purposes and for approved industrial and manufacturing purposes.

PYRINURON

Available only for approved research purposes.

SCHRADAN

Not to be made available in packs for domestic use.

SELENIUM **except**:

(a) when included in or expressly excluded from Schedule 5 or 6; or

(b) as selenium arsenide in photocopier drums; or

(c) in preparations for therapeutic use other than drench concentrates containing 2.5 per cent or less of selenium.

STRYCHNINE (including Nux vomica) **except** when included in Schedule 4

Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

Available for industrial and manufacturing purposes only.

SULFOTEP

Not to be made available in packs for domestic use.

TEPP

Not to be made available in packs for domestic use.

TERBUFOS

Available only for research purposes and industrial and manufacturing purposes in granular form containing 15% or less of the poison and not in packs for domestic use.

TETRACHLOROETHANE

Available only for approved research purposes and approved industrial and manufacturing purposes.

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6

Available only for research purposes.

THALLIUM

Available for use by accredited Government Vermin Control Officers only.

THIOFANOX

Not to be made available in packs for domestic use.

ortho-TOLIDINE

Available only for approved research purposes and approved industrial and manufacturing purposes.

TRIAMIPHOS

Not to be made available in packs for domestic use.

TRIAZBUTIL

Not to be made available in packs for domestic use.

S,S,S-TRIBUTYLPHOSPHOROTRITHIOATE.

TRICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 4 per cent or less of available chlorine.

Available only to authorised or licensed persons for research purposes or for industrial and manufacturing purposes.

VINYL CHLORIDE
Available for approved research purposes and industrial and manufacturing purposes in totally enclosed systems only.

SCHEDULE 8

POISONS TO WHICH THE RESTRICTIONS RECOMMENDED FOR DRUGS OF DEPENDENCE BY THE 1980 AUSTRALIAN ROYAL COMMISSION OF INQUIRY INTO DRUGS SHALL APPLY.

ACETYLDIHYDROCODEINE **except** when included in Schedule 4
ACETYLMETHADOL
ACETYLMORPHINES
ALFENTANIL
ALLYLPRODINE
ALPHACETYLMETHADOL
ALPHAMEPRODINE
ALPHAMETHADOL
ALPHAPRODINE
AMPHETAMINE
AMYLOBARBITONE **except** when included in Schedule 4
ANILERIDINE
BENZETHIDINE
BENZYLMORPHINE
BETACETYLMETHADOL
BETAMEPRODINE
BETAMETHADOL
BETAPRODINE
BEZITRAMIDE
BUTOBARBITONE
BUTORPHANOL
To be used only in horses

CLONITAZENE
COCAINE
COCA LEAF
CODEINE **except** when included in Schedule 2, 3 or 4
CODEINE-N-OXIDE
CODOXIME
CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids)
4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE (Methadone intermediate)
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A)
CYCLOBARBITONE
DEXAMPHETAMINE
DEXTROMORAMIDE
DEXTROPROPOXYPHENE **except** when included in Schedule 4
DIAMPROMIDE

DIETHYLTHIAMBUTENE
DIFENOXIN **except** when included in Schedule 4
DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4
DIHYDROMORPHINE
DIMENOXADOL
DIMEPHEPTANOL
DIMETHYLTHIAMBUTENE
DIOXAPHETYL BUTYRATE
DIPHENOXYLATE **except** when included in Schedule 4
DIPIPANONE
DROTEBANOL
ECGONINE
ETHYLAMPHETAMINE
ETHYLMETHYLTHIAMBUTENE
ETHYLMORPHINE **except** when included in Schedule 2 or 4
ETONITAZENE
ETOXERIDINE
FENETYLLINE
FENTANYL
FURETHIDINE
HYDROCODONE
HYDROMORPHINOL
HYDROMORPHONE
HYDROXYPETHIDINE
ISOMETHADONE
LEVAMPHETAMINE
LEVOMETHAMPHETAMINE
LEVOMETHORPHAN
LEVOMORAMIDE
LEVOPHENACYLMORPHAN
LEVORPHANOL
MECLOQUALONE
METAZOCINE
METHADONE
METHYLAMPHETAMINE
METHYLDESORPHINE
METHYLDIHYDROMORPHINE
2-METHYL-3-MORPHOLINO-1,1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate)
METHYLPHENIDATE
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C)
METOPON
MORPHERIDINE
MORPHINE
MORPHINE METHOBROMIDE
MORPHINE-N-OXIDE
MYROPHINE

NABILONE
NICOCODINE **except** when included in Schedule 4
NICODICODINE **except** when included in Schedule 4
NICOMORPHINE
NORACYMETHADOL
NORCODEINE **except** when included in Schedule 4
NORLEVORPHANOL
NORMETHADONE
NORMOPHINE
NORPIPANONE
OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4
OXYCODONE
OXYMORPHONE
PENTAZOCINE
PENTOBARBITONE **except** when included in Schedule 4
PETHIDINE
PHENADOXONE
PHENAMPROMIDE
PHENAZOCINE
PHENDIMETRAZINE
PHENMETRAZINE
PHENOMORPHAN
PHENOPERIDINE
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B)
PHOLCODINE **except** when included in Schedule 2 or 4
PIMINODINE
PIRITRAMIDE
PROHEPTAZINE
PROPERIDINE
PROPIRAM
QUINALBARBITONE
RACEMETHORPHAN
RACEMORAMIDE
RACEMORPHAN
SECBUTOBARBITONE
SUFENTANIL
THEBACON
THEBAINE
TILIDINE
TRIMEPERIDINE

ENDNOTES

1 KEY

Key to abbreviations

amd = amended
app = appendix
bl = by-law
ch = Chapter
cl = clause
div = Division
exp = expires/expired
f = forms
Gaz* = *Gazette
hdg = heading
ins = inserted
lt = long title
nc = not commenced
od = order
om = omitted
pt = Part
r = regulation/rule
rem = remainder
renum = renumbered
rep = repealed
s = section
sch = Schedule
sdiv = Subdivision
SL = Subordinate Legislation
sub = substituted

2 LIST OF LEGISLATION

***Poisons and Dangerous Drugs Act 1983* (Act No. 4, 1983)**

Assent date	27 April 1983
Commenced	1 October 1983 (*Gaz* G38, 23 September 1983, p 3)

***Statute Law Revision Act 1983* (Act No. 58, 1983)**

Assent date	28 November 1983
Commenced	28 November 1983

***Poisons and Dangerous Drugs (Criminal Code) Amendment Act 1983* (Act No. 67, 1983)**

Assent date	28 November 1983
Commenced	1 January 1984 (s 2, s 2 *Criminal Code Act 1983* (Act No. 47, 1983), *Gaz* G46, 18 November 1983, p 11 and *Gaz* G8, 26 February 1986, p 5)

***Criminal Law (Regulatory Offences) Act 1983* (Act No. 68, 1983)**

Assent date	28 November 1983
Commenced	1 January 1984 (s 2, s 2 *Criminal Code Act 1983* (Act No. 47, 1983), *Gaz* G46, 18 November 1983, p 11 and *Gaz* G8, 26 February 1986, p 5)

***Poisons and Dangerous Drugs Amendment Act 1985* (Act No. 75, 1985)**

Assent date	24 December 1985
Commenced	ss 4, 5, 15 and 19: 4 June 1986; s 16: 1 January 1988; rem: 2 April 1986 (s 2, *Gaz* G22, 4 June 1986, p 4, *Gaz* G41, 14 October 1988, p 4 and *Gaz* G13, 2 April 1986, p 4)

***Statute Law Revision Act 1987* (Act No. 9, 1987)**

Assent date	27 May 1987
Commenced	27 May 1987

***Poisons and Dangerous Drugs Amendment Act 1987* (Act No. 29, 1987)**

Assent date	21 July 1987
Commenced	21 July 1987

***Poisons and Dangerous Drugs Amendment Act 1989* (Act No. 28, 1989)**

Assent date	21 June 1989
Commenced	21 June 1989

***Poisons and Dangerous Drugs Amendment Act 1990* (Act No. 18, 1990)**

Assent date	12 April 1990
Commenced	1 November 1990 (s 2, s 2 *Misuse of Drugs Act 1990* (Act No. 15, 1990) and *Gaz* G40, 10 October 1990, p 3)

***Dental (Consequential Amendments) Act 1991* (Act No. 75, 1991)**

Assent date	10 December 1991
Commenced	31 January 1992 (*Gaz* S7, 31 January 1992)

***Public Sector Employment and Management (Consequential Amendments) Act 1993* (Act No. 28, 1993)**

Assent date	30 June 1993
Commenced	1 July 1993 (s 2, s 2 *Public Sector Employment and Management Act 1993* (Act No. 11, 1993) and *Gaz* S53, 29 June 1993)

***Medical (Consequential Amendments) Act 1995* (Act No. 8, 1995)**

Assent date	10 April 1995
Commenced	1 June 1995 (s 2, s 2 *Medical Act 1995* (Act No. 7, 1995) and *Gaz* S21, 1 June 1995)

***Poisons and Dangerous Drugs Amendment Act 1995* (Act No. 33, 1995)**

Assent date	7 September 1995
Commenced	7 September 1995

***Poisons and Dangerous Drugs Amendment Act (No. 2) 1995* (Act No. 58, 1995)**

Assent date	28 December 1995
Commenced	28 December 1995

***Sentencing (Consequential Amendments) Act 1996* (Act No. 17, 1996)**

Assent date	19 April 1996
Commenced	1 July 1996 (s 2, s 2 *Sentencing Act 1995* (Act No. 39, 1995) and *Gaz* S15, 13 June 1996)

3 *GAZETTE* NOTICES

Gaz S54, 22 October 1984
Gaz S76, 4 November 1986
Gaz G4, 1 February 1989, p 4
Gaz G32, 16 August 1989, p 6
Gaz G14, 11 April 1990, p 6
Gaz G45, 14 November 1990, p 3
Gaz S11, 1 March 1991
Gaz G44, 4 November 1992, p 2
Gaz G38, 22 September 1993, p 2
Gaz S33, 1 November 1996

4 LIST OF AMENDMENTS

s 4	amd No. 58, 1983, s 4
s 6	amd No. 75, 1985, s 4; No. 29, 1987, s 2; No. 75, 1991, s 3; No. 58, 1995, s 3
s 9	amd No. 75, 1985, s 5
s 24	amd No. 75, 1985, s 6
s 26	amd No. 17, 1996, s 6
s 28	amd No. 75, 1985, s 7; No. 8, 1995, s 4
s 29	amd No. 75, 1985, s 8; No. 58, 1995, s 4
s 29A	ins No. 75, 1985, s 9
	amd No. 33, 1995, s 2
s 31A	ins No. 58, 1995, s 5
s 32	amd No. 58, 1995, s 6
s 33	amd No. 75, 1985, s 10; No. 58, 1995, s 7
s 34	amd No. 75, 1985, s 11
s 36	amd No. 75, 1985, s 12
s 39	amd No. 75, 1985, s 13
pt XI hdg	sub No. 75, 1985, s 14
s 52A	ins No. 75, 1985, s 14
	amd No. 9, 1987, s 2; No. 28, 1993, s 3
s 55	amd No. 75, 1985, s 15
ss 56 – 58	amd No. 52, 2003, s 44
s 59A	ins No. 75, 1985, s 16
s 64	rep No. 18, 1990, s 3
ss 64A – 64B	ins No. 28, 1989, s 2
	rep No. 18, 1990, s 3
ss 66 – 70	rep by No. 18, 1990, s 3
s 70A	ins No. 75, 1985, s 17
ss 72 – 77	rep No. 18, 1990, s 3
ss 79 – 81	rep No. 18, 1990, s 3
s 81A	ins No. 68, 1983, s 26
s 81B	ins No. 58, 1995, s 8
ss 82 – 83	rep No. 18, 1990, s 3
s 84	amd No. 67, 1983, s 4
	rep No. 18, 1990, s 3
s 85	amd No. 67, 1983, s 5
	rep No. 18, 1990, s 3
s 88	rep No. 18, 1990, s 3
s 90	amd No. 75, 1985, s 18
s 91A	ins No. 58, 1995, s 9
pt A sch 1	rep No. 18, 1990, s 3
pt A sch 2	amd *Gaz* S76; *Gaz* G32
	sub *Gaz* S11
	amd *Gaz* S33
pt A sch 3	amd No. 58, 1983, s 3
	rep No. 18, 1990, s 3
pt A sch 4	amd *Gaz* S76
	sub *Gaz* S11
pt A sch 5 – 6	rep No. 18, 1990, s 3
pt B sch 1	amd *Gaz* S54; *Gaz* S76
	sub *Gaz* S11
pt B sch 2	amd *Gaz* S54; *Gaz* S76; *Gaz* G14; *Gaz* G45
	sub *Gaz* S11
pt B sch 3	amd *Gaz* S54; *Gaz* S76; *Gaz* G32; *Gaz* G14; *Gaz* G45
	sub *Gaz* S11
	amd *Gaz* G44

pt B sch 4	amd *Gaz* S54; *Gaz* S76; *Gaz* G4; *Gaz* G32; *Gaz* G14; *Gaz* G45
	sub *Gaz* S11
	amd *Gaz* G44; *Gaz* G38
pt B sch 5 – 7	amd *Gaz* S54; *Gaz* S76; *Gaz* G32
	sub *Gaz* S11
pt B sch 8	amd *Gaz* G32
	sub *Gaz* S11